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ABSTRACT
COMPUTATIONAL MODELING OF PROTEIN KINASES:
MOLECULAR BASIS FOR INHIBITION AND CATALYSIS
Yingting Liu
Ravi Radhakrishnan
Protein kinases catalyze protein phosphorylation reactions, i.e. the transfer of the γphosphoryl group of ATP to tyrosine, serine and threonine residues of protein substrates.
This phosphorylation plays an important role in regulating various cellular processes.
Deregulation of many kinases is directly linked to cancer development and the protein
kinase family is one of the most important targets in current cancer therapy regimens.
This relevance to disease has stimulated intensive efforts in the biomedical research
community to understand their catalytic mechanisms, discern their cellular functions, and
discover inhibitors. With the advantage of being able to simultaneously define structural
as well as dynamic properties for complex systems, computational studies at the atomic
level has been recognized as a powerful complement to experimental studies. In this
work, we employed a suite of computational and molecular simulation methods to (1)
explore the catalytic mechanism of a particular protein kinase, namely, epidermal growth
factor receptor (EGFR); (2) study the interaction between EGFR and one of its inhibitors,
namely erlotinib (Tarceva); (3) discern the effects of molecular alterations (somatic
mutations) of EGFR to differential downstream signaling response; and (4) model the
interactions of a novel class of kinase inhibitors with a common ruthenium based
iii

organometallic scaffold with different protein kinases. Our simulations established some
important molecular rules in operation in the contexts of inhibitor-binding, substraterecognition, catalytic landscapes, and signaling in the EGFR tyrosine kinase. Our results
also shed insights on the mechanisms of inhibition and phosphorylation commonly
employed by many kinases.
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Chapter 1 Introduction
1.1 Overview
Most protein kinases reported have been found to share a very similar structure fold,
implicating an overall similarity in their mechanism of enzymatic action. However, as
protein kinases control many different signaling pathways, the details of how they are
regulated and how they recognize and subsequently regulate their substrates are found to
be different. In this work, we focused on a biologically and pharmaceutically important
protein kinase, namely the epidermal growth factor receptor (EGFR) tyrosine kinase
domain (TKD). We employed a suite of molecular and multiscale simulation methods to
investigate mechanisms of substrate recognition and catalysis in EGFR (Chapter 2), the
interaction between EGFR and a small molecule inhibitor (Chapter 3), and the EGFR
signaling network (Chapter 4). We investigated the unique properties of this kinase and
also identified additional conserved properties applicable to homologous kinases. In
chapter 5, we developed and employed a computational protocol to predict the binding of
a novel ruthenium based inhibitors to different protein kinases to understand the
selectivity profile of the new inhibitor scaffold.

1.2 Biological background on protein kinases
Protein kinases, one of the most important targets in the current cancer therapy, are the
largest enzyme family involved in cell signal transduction [24, 124]. They are encoded by
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approximately 2% of eukaryotic genes and more than 500 protein kinases are identified
based on the human genome sequencing [168] and biochemical studies. Protein kinases
catalyze the transfer of the  -phosphate group from an ATP molecule to tyrosine, serine
or threonine residues in proteins. This process plays an essential role in regulating many
fundamental cellular processes [138]. Constitutive or inappropriate activation of protein
kinases are seen in a variety of cancers and small molecule inhibitors are designed to
target/inhibit kinase signaling in such scenarios [61]. Understanding the inhibition and
phosphorylation of protein kinases are significant to guide cancer therapy. Kinases
studied in this work, namely EGFR (our main focus) and other members in the ErbB
family, GSK3-β, CDK2, and PIM1 are all well-established drug targets. The following
sections will describe the background on protein kinases using the EGFR protein kinase
as a template.

1.2.1 Protein kinases play key roles in cellular signaling
Protein kinases play important roles on cellular signaling. A typical example is the ErbBmediated signaling network.

The ErbB family of receptors have received much attention, given their strong
association with malignant proliferation [125]. The family has four members ― the
epidermal growth factor receptor (EGFR or ErbB1 or HER1), ErbB2 (or HER2), ErbB3,
and ErbB4. They activate a multi-layered network mediating crucial pathways, including
Ras-Raf-MAP-kinase, PI3K-Akt, and STAT, leading to cell proliferation, differentiation,
migration and metabolism [63, 120, 218, 281] (Figure 1.1). Over-expression or
mutational modification of the ErbB family are often implicated in a large percentage of
2

clinical cancers of various types [173, 233]. They, especially EGFR and ErbB2, have
already been established as targets in cancer therapy. Small molecule inhibitors for EGFR
are of significant interest as cancer therapeutic drugs [61]. A better understanding of
these receptors is critical to discern the cancer mechanism and will help to design
efficacious drugs.

Figure 1.1 ErbB family signaling network [281].

The ErbB receptors share a common protein structure characterized by an extracellular
region (serves as the ligand binding domain), a transmembrane domain, and an
intracellular tyrosine kinase domain (the focus of this work) flanked by a juxtamembrane
and a C-terminal regulatory region [63, 158]. In the presence of activating ligands,
namely, the epidermal growth factor (EGF), transforming growth factor- (TGF-), and
several other peptide growth factors [63], the family members associate to form
3

homo/hetero dimers, activating their intracellular tyrosine kinases using an unique
allosteric mechanism [289], followed by phosphorylation of several tyrosine residues in
the C-terminal tails. The phosphorylated tyrosines in the C-tails serve as docking sites for
SH2 (Src homology 2) and PTB (phosphotyrosine binding) domains of signaling
proteins, leading to activation of proteins involved downstream in the signaling cascades.

1.2.2 Active and inactive structures of protein kinases
A significant amount of work has been dedicated to characterizing the function of protein
kinases. A fast expanding structural database is continuing to provide valuable insights
into the molecular details of kinase function and regulation. It has been well established
that most protein kinases are highly conversed in both sequence and structures [5]. Owing
to the highly conserved nature of the core structure, a description of EGFR tyrosine
kinase domain (TKD), a typical protein kinase, in this thesis will encompasses the main
features of all members of the kinase family.

Similar to most protein kinases, EGFR TKD shares a two-lobed structural fold, an Nterminal lobe (N-lobe) and a larger C-terminal lobe (C-lobe) (Figure 1.2). The two
domains, connected by a small linker region, form a binding pocket for ATP and the
substrate. Several conserved components near the site of phosphoryl transfer play
important catalytic functions, including the glycine-rich loop (G-loop) and αC-helix in Nlobe, as well as the activation loop (A-loop) and catalytic loop (C-loop) in the C-lobe.

4

Figure 1.2 Key components of EGFR TK (PDBID: 2GS6 [288]).

Like many other kinases, two EGFR TKD conformations, namely active and inactive,
have been captured by crystallography [248, 276, 284, 288]. The active EGFR TKD was
solved both as an apo-kinase (i.e. in isolation) and in the presence of inhibitors, including
erlotinib and gefitinib [248, 284], while the inactive EGFR TKD was crystallized by
mutating a residue critical destabilizing the activating dimer interface or in complex with
a bulky inhibitor, lapatinib. The most notable structural difference between active and
inactive structure of the EGFR TKD is the outward rotation of the αC-helix and the
conformational change of activation loop (Figure 1.3). In a fully active state, the A-loop
adopts an open conformation so that it is positioned away from the catalytic center,
providing a platform for substrate binding [248] (shown in Figure 1.2). The side chain of
the aspartate (Asp831) in the DFG motif is directed into the ATP binding site, which is
required to coordinate Mg2+ and to help orient the  -phosphate group of ATP for
efficient phosphoryl transfer [248, 289]. The αC-helix is positioned toward the catalytic
core, as a result, the catalytic glutamate residue (Glu738) located nearly at the center of
5

αC-helix bridges a lysine residue (Lys721), conserved across several kinases, which is
important in positioning the phosphates of ATP. In contrast, the inactive state is
characterized by an outward shifting of the αC-helix and a closed conformation of the
activation loop. The shift of αC-helix in the inactive EGFR TKD results in the loss of the
Glu-Lys salt bridge and makes the pocket between the two lobes larger, which
accommodate the extra fluorobenzyl-oxy moiety of lapatinib (Figure 1.3).

1.2.3 Protein kinase substrate recognition

Figure 1.3 Active and inactive form of EGFR TKD. Blue: inactive and red: active.

Protein kinases regulate several essential signaling pathways by recognizing [225, 255],
recruiting and phosphorylating a variety of

substrates. Protein kinases poorly

phosphorylate free amino acids and it is believed that the affinity and specificity of
signaling cascades are in-part determined by the sequence identity of phospho-tyrosines
on substrates [226]. That is, the specificity in-part depends on how the kinase recognizes
the local sequence of substrate proteins at the P-site (shown in Figure 1.2), i.e., the amino
6

acids situated immediately proximal to the P-site [142, 261]; the nomenclature for these
resides are P-1, P-2, P-3, etc., for those N-terminal to the P-site, and P+1, P+2, P+3, etc.,
for those C-terminal to the P-site. Experience has suggested that different kinases show
preference for substrates with particular amino acid at the positions close to the P-site
[28, 40, 43, 104]. EGFR TKD, for example, shows preference for substrates with
glutamic acid at the P-1 position and large hydrophobic amino acids at the P+1 position
[118, 123, 149, 245]. The precise relationship of such a sequence identity to substrate
specificity and the catalytic mechanism is still not understood.

Besides the local sequences flanking the P-site, there are many factors influence substrate
specificity of particular protein kinases. For example, CDK2 uses a hydrophobic patch,
RXL, to help recruit its substrate p107, which locates about 40Å away from the site of
phosphoryl transfer [225].

1.2.4 Protein kinase catalytic mechanism
Protein kinases deliver a single phosphoryl group from the gamma position of ATP to the
hydroxyls of serine, threonine, and tyrosine in protein substrates. Extensive efforts have
been made to understand the details of this phosphoryl transfer reaction. The cAMPdependent protein kinase (PKA) is by far the best understood protein kinase from this
point of view [167] and substantial progress has also been made with other kinases [16,
17, 30, 41]. Although several details are yet to be resolved, a common mechanism
believed to be in operation among kinases can be defined:
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1) Mg2+ ions are involved in the reaction. One Mg2+ ion is believed to be essential for
catalysis [5]. This metal ion is chelated Mg2+ by the phosphates of ATP and one
conserved aspartic acid (as observed in the crystallographic structure of PKA,
PDBID:1ATP) [167, 256, 292]. A second metal ion is also observed in the active site
of some enzymes when the crystal is soaked with high concentration of Mg2+ ions.
The coordination of this metal varies among the different structures available [5].

Figure 1.4 Stereo view of Mg2ADP, AIF3, SP20 (substrate serine), and catalytically important residues in
the catalytic subunit of cAMP-dependent protein kinase.

2) In phosphoryl-transfer by kinases and polymerases, nucleophilic attack on the target
phosphate proceeds via a conformation that resembles a trigonal-bipyramidal
transition state [154, 249], shown in Figure 1.4.
3) The phosphoryl-transfer can occur through either an associative or a dissociative
mechanism [64] (showed in Figure 1.5). In the dissociative mechanism, the cleavage
of the bond between the phosphorus center and the leaving group oxygen precedes
8

the bond formation with the attacking nucleophile. On the contrary, in associative
mechanism, the bond formation between the attacking nucleophile and the
phosphorus center precedes the bond cleavage. Although it is well accepted that the
dissociative mechanism is the preferred mechanism for reaction in solution for
monoester [29, 145, 175, 220, 292] which are particularly relevant for the reaction
catalyzed by protein kinases, discerning the transition state of protein kinase
catalyzed reaction is complex, resulting in controversial experimental interpretations
[145, 167, 294].

Figure 1.5 Dissociative vs. associative mechanisms for phosphoryl transfer [5].

4) The potential roles of specific residues around catalytic site are still not clearly
understood. There is a debate over the role of the conserved aspartic residue (D813
in EGFR or D166 in PKA) in the catalytic loop [160]. This conserved aspartate is
clearly important for efficient catalysis. Replacement of this residue with alanine in
PKA and PhK results in decrease in kcat by 2-4 orders of magnitude [100, 241].
However, the potential function of this conserved residue is ardently debated. The
facts that in PKA as well as in other kinases, the aspartate (D166 in PKA) forms a
9

hydrogen bond with the substrate peptide and that the second-order rate constant,
kcat/Km, for the phosphorylation of peptides is pH sensitive, support a general-base
mechanism [282]. However, it is also shown that high negative charge on the
hydroxyl could inhibit the reaction if charge repulsion with the γ phosphate is
considered [145], which limits the advantage of a general base reaction mechanism.
Another proposal is that the carboxyl group may position the hydroxyl for productive
attack of the γ phosphate of the ATP and the proton would not be transferred to the
aspartate. Computational modeling methods may serve to further clear this debate.

1.2.5 Pharmacophore model of kinases and ATP-competitive inhibitors

Figure 1.6 Pharmacophore model of the ATP-binding site of protein kinases. ATP is in red. Sug1, Hyp1,
and Hyc1, Hin are residues lining the sugar region (Sug), hydrophobic pocket (Hyp), hydrophobic channel
(Huc) and the hinge region respectively [82].

Protein kinases have been identified as one of the most important targets in the current
cancer therapy. One of ways to inhibit abnormal kinase activity is to design small
10

molecule inhibitors to bind into the ATP binding cleft, block ATP binding and therefore
inhibit the phosphorylation. The success of small-molecule ATP-competitive inhibitors
such as imatinib (Gleevec) for the treatment of chronic myeloid leukemia (CML) and
gastrointestinal stromal tumors (GIST) confirmed that this strategy is indeed effective
[42]. In spite of the success of Gleevec, the design of ATP-competitive inhibitors that are
selective (specific) for a particular kinase appears to be quite challenging due to the
conserved nature of protein structures.

X-ray crystal structures for a range of kinases are available in the Protein Data Bank
(PDB), which provide structural basis for understanding kinase inhibition and facilitate
structure-guided design of kinase-specific inhibitors. The catalytic clefts of protein
kinases usually include two hydrophobic pockets (Hyp1 and Hyc1), adenine region,
„sugar‟ pocket and the phosphate groove, shown in Figure 1.6. The adenine region
contains the two key hydrogen bonds formed by the interaction of the N-1 and N-6 amino
groups of the adenine ring with the backbone NH and carbonyl groups of the adenine
anchoring hinge region (Met769 in EGFR) of the protein kinase. Many potent inhibitors
use at least one of these hydrogen bonds. The hydrophobic pocket is not used by ATP,
but is exploited in the design of most kinase inhibitors. It plays an important role for
inhibitor selectivity, and its size is different in active and inactive kinase states. The
hydrophobic channel opens to solvent and is not used by ATP and hence, it can be
exploited in the design of inhibitors. The phosphate binding region offers little
opportunity in terms of inhibitor binding affinity due to high solvent exposure. However,
it can be utilized in improving selectivity.
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1.3 Computational methods and their applications in biological
studies
Besides the chemical approaches, computational methods (described below) are also
widely used to understand the inhibition and phosphorylation mechanism of protein
kinases.

1.3.1 Molecular dynamics (MD) simulations
Empirical force field-based molecular dynamics (MD) simulations [19] are widely
applied to refine molecular structures, obtain information on the time evolution of
conformations that is otherwise elusive. Along with a range of complementary
computational approaches, MD simulations have the ability to analyze the relationship of
structures to energies, which experimental approaches can only access indirectly, and
thus have become invaluable for structure/function analyses in proteins.

To perform MD simulations, the starting point is defining the initial coordinates and
initial velocities of the atoms characterizing the model system, for example, the desired
biomolecule plus the biologically relevant environment; i.e. water molecules or other
solvent and/or membranes. The coordinates of the desired biomolecule can usually be
found as structural data (X-ray or NMR) deposited into the protein data bank (PDB);
otherwise it is possible to derive initial geometry and coordinate data from model
building techniques, including homology methods. This step also typically includes the
placement and positioning of the environment of the molecules (solvation, ionic strength
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etc.).

The initial velocities are typically derived from the Maxwell-Boltzmann

distributions at the desired temperature of the simulation. The potential of interactions of
each of the atoms are calculated using a force field, which parameterizes the non-bonded
and bonded interaction terms of each atom depending on its constituent atom
connectivity: bond terms, angle terms, dihedral terms, improper dihedral terms, nonbonded Lennard-Jones terms, and electrostatic terms.

The potential interactions are

summed across all the atoms contained in the system, to compute an overall potential
energy function for the system [103]:

Taking the derivative of the potential energy function yields the force, and from
Newton‟s second law, this is equal to mass times acceleration. Although, the process
seems simple, the derivative function results in a set of 3N-coupled 2nd order ordinary
differential equations that must be solved numerically.

The solution consists of a

numerical recipe to advance the positions and the velocities by one time step. This
process is repeated over and over again to generate MD trajectories of constant energy.
Constant temperature dynamics are derived by coupling the system to a thermostat using
well established formulations such as the Langevin dynamics or the Nose-Hoover
methodologies [37]. Application of MD simulations to biomolecules is facilitated by
several popular choices of force fields such as CHARMM27 [271] (www.charmm.org),
AMBER [227] (www.ambermd.org), and GROMOS[192] (www.gromacs.org), as well as
13

dynamic simulations packages and visualization/analysis tools such as NAMD [122]
(www.ks.uiuc.edu/Research/namd/) and VMD [206] (www.ks.uiuc.edu/Research/vmd/).
With analysis of molecular dynamics trajectories, it is possible to calculate statistical
properties under a variety of initial and other external conditions [162] such as hydrogen
bond analyses for hydrophilic interactions and solvent accessible surface area for
hydrophobic interactions.

For example, by analyzing the relative positions of the

hydrogen bond donors to the hydrogen bond acceptors with a preset cutoff angle and a
bond length, the hydrogen bonds present in the majority of a given trajectory can be
identified to record permanent stabilizing interactions and differentiate them from
transient interactions [169, 170]. Similarly, using the solvent accessible surface area
analysis, i.e. by mapping a surface area created using a probe sphere of 1.4 Å and
accumulating the statistical data, provides a quantitative metric of hydrophobic
stabilization effects.
The utility of MD simulations generally depend on the accuracy of the underlying forcefield. Since force-fields are created using empirical energy functions, they are
parameterized and tuned to specific class of molecules; this introduces a constraint on
their transferability to model non-native systems or environments and results must often
be compared to experimental results, not only to verify their accuracy, but also to identify
where methodological improvements can be made. Thus, there is continued development
of the basic force-field as well as the simulation methodology.
Another important consideration is the ability to perform sufficient sampling of the
combinatorially large number of conformations available to even the simplest of
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biomolecules [81]. In this respect, a potential disadvantage of molecular dynamics
calculations is that there is an inherent limitation upon the maximum time step used for
the simulation (≤ 2 fs). Solvated systems of protein monomers typically consist of 40000
atoms, and those of higher order complexes such as dimers or membrane-bound proteins
can be as large as 200,000 to 500,000 atoms. For such system sizes, with current
hardware and software, simulation times extending into the microsecond regime and
beyond is an exceedingly difficult and labor intensive endeavor which requires a
combination of algorithmic enhancements as well as the utilization of high-performance
computing hardware infrastructure. For example, cutoff distances reduce the number of
interactions to be computed without loss of accuracy for short-range interactions but not
for long-range (electrostatic) interactions; to help maintain accuracy, long-range
corrections such as the particle mesh Ewald algorithm [105, 252] along with periodic
boundary conditions are typically implemented. Parallelization techniques enable the
execution of the simulations on supercomputing resources such as 4096 processors of a
networked Linux cluster.

Although a cluster of this size is a big investment, its

accessibility is feasible through the US National Science Foundations‟s TeraGrid
Initiative

(founded

in

2001)

for

academic

researchers.

TeraGrid

resources

(www.teragrid.org) currently include more than a petaflop of computing capability and
more than 30 petabytes of online and archival data storage, with rapid access and
retrieval over high-performance networks. Capitalizing on advances in hardware
architecture, another approach is the creation of custom hardware for MD simulations,
and offers one-two orders of magnitude enhancement in performance; examples include
MDGRAPE-3 [230, 232] and ANTON [95, 251]. Recently, graphical processing unit
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(GPU) accelerated computation has come into the forefront to enable massive speed
enhancements for easily parallelizable tasks with early data indicating that GPU
accelerated computing may allow for the power of a supercomputing cluster in a desktop,
see examples [36, 109].

1.3.2 Molecular docking
Molecular docking can be defined as the prediction of the “correct” bound structure of
the complex involving a receptor (typically a protein) and a ligand (other proteins,
nucleic acids or small molecule inhibitors) [181]. The idea behind docking is to generate
a comprehensive set of conformations of the receptor-ligand complex and then to rank
them according to their stability. One essential component for the success of a docking
program is an algorithm for conformational space searching. Ideally, conformational
searching during docking for both receptor and ligands are necessary. However, to
enhance computational efficiency, ligand flexibility is considered by most existing
softwares, while receptors (or proteins) are usually treated as rigid during docking.
However, the frequently observed changes in receptor structure upon ligand binding
indicate the importance of receptor flexibility [274] and different versions of receptor
flexible models with varying degrees of sophistication have been proposed. Among them,
using MD simulations to pre-generate protein conformers for docking [178] will be used
in this thesis. Another essential part of a docking program is a fast yet accurate scoring
function. Many docking programs, for reasons of computational efficiency, usually
approximate the binding free energy based on the evaluation of a single structure. These
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scoring functions usually assume that the binding free energy can be estimated by a linear
combination of pairwise terms [204]:

G  GvdW  Ghbond  Gelec  Gconform  Gtor  Gsol

where, the first four terms are molecular mechanics terms, namely, dispersion/repulsion,
hydrogen bonding, electrostatics and deviations from the covalent geometry; the fifth
term models the restriction of internal rotors and global rotation and translation; and the
last term accounts desolvation upon binding and the hydrophobic effect. This class of
scoring functions is of practical use for molecular docking and is computationally
tractable. On the other hand, they certainly have limitations in terms of the accuracy with
which they represent the free energy of binding due to the various simplifying
assumptions.

1.3.3 Free energy perturbation (FEP)

Figure 1.7 Thermodynamic cycle for the calculation of binding affinity change of ligand/substrate due to a
mutation.
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In this thesis, we designed a thermodynamic cycle as shown in Figure 1.7 and employed
the free energy perturbation (FEP) method to calculate the effect of how mutation will
affect small molecule binding. To calculate the binding free energy change

, we

can calculate the difference between the free energy changes caused by the particular
mutation in the bound state (

) and the unbound state (

). The binding affinity

change due to the mutation can be expressed as:

The free energy changes caused by the particular mutation in the bound state (
the unbound state (

) and

) were calculate by free energy perturbation (FEP) method. In

general, the free energy difference between two related system A and B, represented by
the Hamiltonians of

and

can be calculated by

where R is Boltzmann's constant, T is the temperature, and

refers to an ensemble

average over a simulation run for state A.

In our simulation, systems A and B are defined by the wildtype and mutation states of
bound or unbound system. In order to improve accuracy, the two thermodynamic states
are broken into windows, each one involving a small enough interval to allow the
incremental free energy change to be calculated accurately. A Hamiltonian
defined as
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is

Where can vary from 0 (

) to 1 (

). The accumulated free energy change is

calculated by:

.

1.3.4 MMPBSA
While approximate binding free energies are suitable for high-throughput docking,
stringent rankings or accurate free energies are often needed for lead optimization and
more detailed examination of binding at the molecular level. Thermodynamic integration
(TI) and free energy perturbation (FEP) [150, 253] are among the most rigorous free
energy methods available currently. However, they are too computationally expensive to
be widely employed. MD-based methods such as Molecular Mechanics PoissonBoltzmann Surface Area (MMPBSA) [153] can achieve similar accuracy at a smaller
computational cost, therefore commonly used for virtual screening of compounds. It has
produced reasonable binding energies for several systems, and also been employed as a
post-docking filter in the virtual screening of compounds [136, 188, 254]. In this thesis,
we use MMPBSA to re-rank the top predicted bound conformation generated by
molecular docking.

In a MMPBSA method, the binding affinity between ligand (L) and the protein receptor
(R) is estimated from the free energies of three species,
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where all species are assumed to be in water solution. The free energy of each of the
species is estimated as a sum of four terms:

where

is the polar solvation energy of the molecule, estimated by the solution of the

Poisson-Boltzmann (PB) equation,

is the nonpolar solvation energy, estimated form

the solvent-accessible surface area of the molecule, T is the temperature,

is the

entropy of the molecule, estimated from a normal-mode analysis of harmonic frequencies
calculated at the molecular mechanics (MM) level, and

is the MM energy of the

molecule, i.e., the sum of the internal energy of the molecule (i.e., bonded terms), the
electrostatics and van der Waals interactions. All the terms in the above equation are
averages of energies obtained from a number of snapshots taken from MD simulations.
As the computationally most intensive step of the MMPBSA method is the generation of
snapshots (geometries) employed in the energy calculations through MD simulations, in
order to minimize computing resources, the same geometry is employed for all three
species (complex, ligand, and receptor), i.e., only the complex is simulated by MD.
Thereby, the bonded term in MM energy cancels out in the calculation.
The MMPBSA model, like other implicit models, is derived from the potential of mean
force based on the assumption that electrostatic and nonpolar contributions to the free
energy can be treated separately in a additive fashion (this represents a mean-field
assumption). In the MMPBSA approach, we calculate the salvation terms based on a predefined model for atomic radii and solute dielectric constant, which are simplifying
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assumptions. The method also makes simplifying assumptions on conformational
sampling in order to gain efficiency.

1.3.5 Electronic Structure Methods
Molecular simulations using the empirical force-field approach are rooted in the validity
of classical mechanics. Electronic structure methods [71, 89, 96, 99, 196, 207, 209, 228,
240, 268, 269, 290] that relieve this fundamental assumption are often necessary in forcefield development as well as in understanding chemical reaction pathways and catalytic
mechanisms. While electronic structure methods are computationally rather demanding,
recent advances in mixed quantum mechanics molecular mechanics (QM/MM) methods
also enable us to combine high level electronic structure methods with molecular
mechanics [22, 44, 46, 68, 72, 76, 78, 87, 88, 106, 127, 128, 146, 157, 178, 190, 191,
221, 243, 279, 280, 283, 285, 286, 296]. This multiscale description of force-fields
provides a route to extend the electronic structure methods to the nanometer scale to
enable the study of biomolecular systems. Compared to their classical counter-parts [268,
269], the quantum approaches (such as the empirical valence bond [13, 67, 92, 99, 108,
291]) and mixed QM/MM approaches are more challenging to apply in the biochemical
context, though several successful demonstrations are available [3, 166]. In this thesis, we
employed electronic structure methods in force-field development as well as in the study
of catalytic reaction mechanisms.
Electronic Structure Methods in Force-field Development: In order to obtain an accurate
description of molecular parameters (force-field), we require specification of geometric
parameters such as bond, angle, dihedral angles etc., energetic terms such as partial
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charges, bond/angle/dihedral stiffness, and contributions of solvation-desolvation.
Consistent with existing biomolecular force-fields, it is thus essential to parameterize any
new compound/molecule/chemical modification in the model and extend the force field
for accurate representation of the model system.This procedure usually involves a series
of steps [254] described below. The geometry of new compounds is optimized using an
electronic structure method such as Hartree-Fock (HF) [254] and by using a set of basis
functions to represent the electronic wave function. Such calculations are facilitated by
the aid of the quantum chemistry software such as GAUSSIAN (www.gaussian.com
[91]). The procedure of geometry optimization of the molecule returns the equilibrium
geometry of the molecule, the spatial electron-density at 0 K, from which the partial
(Mulliken) charges on each atom are inferred. Moreover, the frequency spectrum of the
molecule to characterize its vibration spectrum in the ground state is also computed using
the analysis of normal modes. In order to represent delocalized (low-frequency) motions
such as torsional oscillations, a torsional energy scan is also performed.
In determining empirical force field parameters for new compounds, consistency and
compatibility with the parent force-field is an important criterion. For example, the
CHARMM27 force-field is commonly used as an all-atom empirical force field for
biomolecules; it is therefore necessary to develop force-field parameters for new
compounds consistent with the rest of the CHARMM27 force-field.
To obtain these parameters [33], partial atomic charges are calculated using CHarges
from ELectrostatic Potentials using a Grid based method (CHELPG) [178] in
GAUSSIAN and further adjusted to reproduce interaction energy of H-bond
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donor/acceptor atoms in the inhibitor compound with water molecules. The
intramolecular parameters such as molecule geometry and force constants are determined
by using structural and vibrational data derived from electronic structure calculations.
Intramolecular force constants are initially assigned based on existing parameters of
compounds with similar structure and further refined following an automatic procedure
using a genetic algorithm (GA) to optimize a merit function [263], which matches both
eigenvalues and eigenvectors estimated using the electronic structure calculations (i.e.
using GAUSSIAN) to those resulting from a normal mode analysis calculated from
classical molecular mechanics calculations, i.e. using CHARMM [228, 268].
Quantum Mechanics Molecular Mechanics (QM/MM) Simulations: In the QM/MM
simulations, the system is sub-divided into two sub-regions, the quantum mechanical subregion (QM region) where the reactive events take place, and the molecular mechanical
sub-region (which provides the complete environment around the reactive chemistry)
[188]. Since electronic structure methods are limited by the number of atoms they can
handle (typically 50-500), the QM sub-region is restricted to a small number of atoms of
the total system. For example, in an enzymatic system, the quantum region can consist of
Mg2+ ions, water molecules within 3 Å of the Mg2+ ions, parts of the substrate molecules
and the catalytic amino acid residues (such as aspartic acids). The remaining protein and
solvent molecules are treated classically using the regular classical force-field (such as
CHARMM27).
In QM/MM simulations, wave function optimizations are typically performed in the
quantum (or QM) sub-region of the system using an electronic structure method such as
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density functional theory (DFT) [180, 228]. In this step, the electrostatic coupling
between the QM and the MM sub-regions is accounted for: i.e., the charges in the MM
sub-region are allowed to polarize the electronic wave functions in the QM sub-region.
The forces in the quantum sub-region are calculated using DFT, on-the-fly, assuming that
the system moves on the Born-Oppenheimer surface [89]. That is, we assume a clear
timescale of separation between the electronic and nuclear degrees of freedom and the
electronic degrees of freedom are in their ground state around the instantaneous
configurations of the nuclei. The forces on the classical region are calculated using a
classical force-field. In addition, a mixed Hamiltonian (energy function) accounts for the
interaction of the classical and the quantum sub-regions. For example, since the QM/MM
boundary often cuts across covalent bonds one can use a link atom procedure [71] to
satisfy the valences of broken bonds in the QM sub-region. Also, bonded terms and
electrostatic terms between the atoms of the QM region and those of the classical region
are typically included [222].
From a practitioner‟s stand-point, QM/MM methods are implemented based on existing
interfaces between the electronic structure and the molecular dynamics programs, one
implementation is between GAMESS-UK (www.cfs.dl.ac.uk [37]) (an ab-initio
electronic structure prediction package) and CHARMM [71]. The model system can then
be subjected to the usual energy minimization and constant temperature equilibration
runs at the desired temperature using the regular integration procedures in operation for
pure MM systems; it is customary to carry out QM/MM dynamics runs (typically limited
to 10-100 ps because of the computationally intensive electronic structure calculations)
using a standard 1 fs time step of integration. The main advantage of the QM/MM
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simulations is that one can follow reactive events and dissect reaction mechanisms in the
active site, while considering the explicit coupling to the extended region. In practice,
sufficient experience and care is needed in the choices of the QM sub-region and the
many alternative choices of system sizes, as well as the link-atom schemes need to be
compared to ensure convergence and accuracy of results [290]. The shorter length of the
dynamics runs in the QM/MM simulations (ps) relative to the MM MD simulations (ns)
implies that sufficiently high resolution structures are usually necessary for setting up
such runs as the simulations only explore a limited conformational space available to the
system. Another challenge is an accurate and reliable representation of the mixed
QM/MM interaction terms [238, 295]. These challenges are currently being overcome by
the suitable design of next generation methods for electronic structure and molecular
mechanics simulations [52, 193].
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Chapter 2 Computational

Delineation

of

Tyrosyl-

Substrate Recognition and Catalytic Landscapes in the
Epidermal Growth Factor Receptor Tyrosine Kinase
Domain
2.1 Introduction
The recent availability of several crystal structures of the EGFR kinase domain [15, 248,
284, 289] together with the identification of several kinase-activating mutations [48, 164,
186] clinically related to enhanced drug response have brought to focus the importance of
molecular details in the structure-function relationship, including mechanisms for
substrate recognition and phosphoryl transfer.

Figure 2.1 Structure of EGFR TKD co-crystallized with the bi-substrate analogs.
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EGFR tyrosine kinase domain (TKD) is a typical tyrosine protein kinase, which catalyzes
protein phosphorylation reactions by transferring the γ-phosphate group from an ATP
molecule to the hydroxyl group of tyrosine residues in protein substrates [5]. It shares
bilobe-fold catalytic domain common to several kinases [5, 30, 110] implying a
conserved catalytic mechanism [5, 30, 110] in which ATP binds into the cleft between
the N- and the C- lobes. In addition, two divalent metal (magnesium) ions are thought to
be involved in the catalytic reaction [5, 110, 145, 256] along with a number of highly
conserved regions in the catalytic domain, including the glycine-rich loop, the DFG motif
of the activation loop as well as the catalytic loop serving to position the phosphate of
ATP and the two Mg2+ ions. Then, by recognizing [225, 255], recruiting and
phosphorylating a variety of peptide substrates, the kinase regulates several essential
signaling pathways. Even though a complete elucidation of specificity in tyrosine
phosphorylation by TKDs continues to be elusive[177], it is believed that the specificity
of signaling cascades are in-part determined by the sequence identity of phosphortyrosines on substrates [226]. That is, the specificity in-part depends on how the kinase
recognizes the local sequence of substrate proteins at the P-site (shown in Figure 2.1),
i.e., the amino acids situated immediately proximal to the P-site [142, 261], denoted by P1, P-2, P-3, etc. on the N-terminal side and P+1, P+2, P+3, etc. on the C-terminal side. It
has been suggested that receptor tyrosine kinases including EGFR TKD show preference
for substrates with glutamic acid at the P-1 position and large hydrophobic amino acids at
the P+1 position [118, 123, 149, 245]. The precise relationship of such a sequence
identity to substrate specificity and the catalytic mechanism is still not understood.

27

Experimental and theoretical studies have demonstrated that, in phosphoryl-transfer by
kinases and polymerases, nucleophilic attack on the target phosphate proceeds via a
conformation that resembles a trigonal-bipyramidal transition state [154, 249]. However,
the phosphoryl-transfer can occur through either an associative or a dissociative
mechanism (39, 41-44). In the dissociative mechanism, the cleavage of the bond between
the phosphorus center and the leaving group oxygen precedes the bond formation with
the attacking nucleophile. On the contrary, in associative mechanism, the bond formation
between the attacking nucleophile and the phosphorus center precedes the bond cleavage.
Although it is well accepted that the dissociative mechanism is the preferred mechanism
for reaction in solution for monoester [64] which are particularly relevant for the reaction
catalyzed by TKDs, discerning the transition state of protein kinase catalyzed reaction is
complex, resulting in controversial experimental interpretations [29, 145, 175, 220, 292].
Besides, it is also important to understand the catalytic roles of specific residues around
catalytic site of a protein kinase, in particular, the role of the conserved aspartic residue
(D813 in EGFR) in the catalytic loop [145, 167, 294]. To address this question in other
well-characterized kinase systems such as PKA, CDK2, insulin kinase, and MAPK,
computational methods have been successfully used to investigate the phosphoryl transfer
reaction [52, 53, 73, 74, 97, 260, 264, 293]. The challenge in extending such studies to
EGFR kinase is that, while the structure for EGFR crystallized with a bi-substrate (ATPpeptide analog) is available [289] providing molecular resolution to the ternary complex
of the kinase/substrate/ATP system, the covalent constraint between the ATP analog and
the substrate and the fact that the peptide sequence in the bi-substrate ligand is a c-Src
[159, 288] rather than a native EGFR substrate introduce an important challenge in
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resolving the structural details of the catalytically productive ternary complex [28]; this
brings to focus a related but equally important question on how EGFR kinase recognizes
its native peptide substrates.
In this chapter, we employ methods of molecular modeling and simulation to (1)
investigate how the EGFR TKD recognizes the local amino acid sequence of substrates
proximal to the P-site as, and (2) characterize the EGFR TKD-catalyzed mechanism of
phosphoryl transfer. Specifically, to address (1) we employ a computational protocol
combining molecular dynamics simulations, ensemble molecular docking [161, 274],
and Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) [102, 117, 150,
153, 231, 253, 266] to investigate the bound conformations of peptide substrates derived
from two of autophosphorylation sites of the cytoplasmic tail (C-terminal) region of
EGFR TKD [123], namely Y1068 (VPEYINQ) and Y1173 (NAEYLRV). We find that in
our predicted bound conformations, the substrates bound into the same pocket as the bisubstrate peptide and that the P-1 glutamic acid residue and the hydrophobic amino acid
at the P+1 position situate to interact with a highly conserved motif in the protein kinase
family, namely Val852-Pro853-Ile854-Lys855-Trp856 in EGFR. This motif creates a
binding surface to form hydrophobic contacts as well as hydrogen bonds to residues close
to P-site (P0) tyrosine in the substrate and therefore helps to orient the tyrosine residue
towards the active site. Using our predicted binary complex of EGFR TKD/substrate, we
modeled the ternary complex structure of EGFR TKD/substrate/ATP and two Mg2+ ions,
and address (2) by investigating the phosphoryl transfer of EGFR TKD using mixed
quantum mechanics molecular mechanics (QM/MM) simulations. Our QM/MM
simulations show that the EGFR protein kinase favors the dissociative mechanism,
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although an alternative channel through the formation of an associative transition state is
also possible. Our potential energy scans suggest that the kinase directs the reaction
through the dissociative channel primarily using a hydrogen bond between the conserved
aspartic acid residue in the catalytic loop and the hydroxyl group of the substrate. The
alternative channel can sustain weak activity, but can become significant in non-cognate
environments where the catalytic aspartic acid is mutated or the enzyme is locked in a
constitutively inactive conformation. Collectively, our simulations establish key
molecular rules in operation for the substrate-binding and catalytic landscapes in the
EGFR TKD.

Figure 2.2 Docking protocol to predict peptide bound conformation to EGFR TKD

2.2 Methods and Materials
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We employ a suite of computational methods including molecular dynamics and
molecular docking (see Figure 2.2), umbrella sampling, and QM/MM simulations to
investigate molecular mechanisms of substrate recognition (i.e. bound conformation of a
tyrosyl-peptide) by EGFR TKD and the catalytic mechanism associated with the
subsequent phosphoryl transfer reaction.

2.2.1 Molecular dynamics
All the molecular dynamics simulations in this thesis started with preparing the protein or
protein complex structure by adding hydrogen atoms and missing residues using the
CHARMM [37] biomolecular simulation package. The protonation states of histidine
(HIS) residues were chosen according to recommendations from the WHATIF web
interface (http://swift.cmbi.kun.nl/WIWWWI). Protonation states for all titratable groups
distal to the catalytic site were chosen based on their individual pKa values in aqueous
solution at a pH 7.0 [200]. The systems were then placed in a water (TIP3 model) box
with 15Å padding with ions added randomly to neutralize the systems using the Solvate
and Autoionize Plug-ins in VMD package [121]. The systems were minimized for 50000
steps with heavy atoms fixed and relaxed for another 50000 steps without any restraints.
The systems were then gradually heated from 0K to 300K followed by 500ps
equilibrating runs at constant pressure and temperature to allow the system to reach the
proper density. A productive trajectory was then generated at 300K and 1atm. The
simulations were performed using NAMD with CHARMM force field [166] with
periodic boundaries enforced and long-range electrostatics taken into consideration.

2.2.2 Molecular docking
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All the docking simulated in this thesis were performed with AUTODOCK 3.05 [178].
Grid maps were constructed as 126126126 points with a grid spacing of 0.184 Å to
cover the pre-defined binding pocket. The Lamarckian Genetic Algorithm (LGA)[178]
was applied to explore the conformational space of the substrate. In each docking run, the
initial population was set to 100 individuals; the maximum number of energy evaluations
is set to 108; and the generation of GA run is set to 30,000.

2.2.3 Docking of substrate tyrosyl-peptides Y1068 and Y1173 to EGFR
TKD
The active conformation of the wildtype EGFR TKD domain was modeled based on the
2GS6 structure from the Protein Data Bank [289]. A 10 ns dynamics trajectory was
generated by molecular dynamics simulation and an ensemble of 100 protein
conformations was derived by sampling at uniform intervals from the trajectory. Two 7residue peptides derived from the c-terminal region of EGFR (corresponding to Y1068:
namely, VPEYINQ and to Y1173: namely, NAEYLRV) were docked to each snapshot in
the 100-member ensemble by molecular docking. Five possible bound conformations
were predicted for each protein conformation, which in total yielded 500 bound
conformations of tyrosyl-peptide/EGFR TKD for each peptide.
Since no constraints were imposed in the docking simulation, we employed a screening
filter to identify those conformations in which the tyrosine-hydroxyl oxygen Y(P0):Oη
was situated <6 Å from the O2 oxygen of the conserved catalytic aspartic acid residue
(D813). The choice of 6 Å as the filter-cutoff was made to accommodate direct as well as
water-mediated hydrogen bonding between the respective groups. The resulting
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structures were aligned (based on the protein backbone) to the crystal structure of EGFR
TKD in complex with the bi-substrate ligand, namely 2GS6; conformations in which the
peptide overlaps with ATP conformation in the bi-substrate structure were further
discarded. Hence, out of the 500 predicted conformations, only 18 of them satisfied the
constraints of our filter and were organized into 5 clusters based on RMSD (based on the
backbone atoms and a cluster cutoff value of 3.0Å). In each cluster, we identified the
conformation with the lowest binding energy score as the representative for further
analysis.
In order to further sort the binding conformations generated by the ensemble docking
protocol, we employed MMPBSA [102, 117, 150, 153, 231, 253, 266] to calculate the
binding free energy. For each of the predicted bound conformations, a 1 ns trajectory was
generated using molecular dynamics. The MMPBSA energy of each modeled complex
was calculated as the average of the single point MMPBSA scores of 500 snapshots
derived from the 1 ns simulation; the waters molecules and mobile ions were removed
before the MMPBSA score calculation. In the MMPBSA calculation, the molecular
mechanics energy, UMM, was evaluated using an infinite cutoff for non-bonded
interactions. The electrostatic contribution to the solvation free energy, WPB, was
calcuated with Poisson-Boltzmann Solver in CHARMM [126]. The reference system was
assigned a solvent dielectric of 1 and 0 M salt concentration and the solvated system was
assigned a dielectric of 80.0 and 100 mM salt concentration. The nonpolar contribution to
the solvation free energy, WSA, was approximated with the suface area model
WSA=[0.00542 kcal/mol/Å2]SASA +0.92 kcal/mol [215], where the molecular surface
area (SA) was estimated with a 1.4 Å slovent probe radius. The translational and rotional
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entropy loss upon binding was estimated based on the change of freedom of center of
mass as well as orientations (Eular Angles) by following the procedure described by
Swanson et.al. [253] . Other (vibrational) entropy changes were neglected in this thesis.
The top-ranked conformation of peptide Y1068 with EGFR TKD identified based on the
MMPBSA score was chosen as the initial bound structure for further analysis of the
catalytic mechanism. The ATP was placed in homology with the bi-substrate structure
(PDB ID: 2GS6) [289] and two Mg2+ ions were placed in homology with those resolved
in the crystal structure of PKA (PDBID:1ATP) [52]. A 10 ns molecular dynamics
simulation was performed on the ternary complex of ATP/substrate-Y/EGFR TKD.

2.2.4 Sampling the Pre-Catalytic Free Energy Landscape
Since the positions and orientations of the ions and ATP relative to the substrate tyrosines
in our initial modeled structures were determined either from a bisubstrate ligand
complex or by homology with protein kinase A (see above), prior to QM/MM
simulations, we explored the classical free energy landscape along an a priori-chosen
reaction coordinate 1 (the tyrosyl O-ATP P nucleophilic attack distance). For
computing the free energy landscape, the probability distribution P( 1) is calculated by
dividing

1

into several (6-7) windows. The histograms for each window were collected

by harvesting classical molecular dynamics trajectories of length 200 ps per window
using a harmonic restraint 0.5×K×(

1- 1

i,0 2

),

1

i,0

being the pre-set of the reaction

coordinate characterizing the ith sampling window, and K=20 kcal/mol/Å2 being the force
constant for the restraint along

1.

The sampling data from the different windows were

then processed using the weighted histogram analysis method (WHAM) [213].
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2.2.5 Quantum Mechanics Molecular Mechanics (QMMM) Simulations
The QMMM approach we adopted was based on an existing interface between
GAMESS-UK [222] and CHARMM [37]. For the quantum region, we chose the two
Mg2+ ions, water molecules within 5 Å of the Mg2+ ions, segments of the ATP, the
tyrosine residue of the substrate, and two catalytic residues (D813 and D831), yielding a
total of 60 atoms . In order to reliably handle the phosphorous chemistry, the quantum
region was treated using density functional theory with a B3LYP exchange correlation
functional and a 6-31G* basis set [254], and the remaining protein and solvent molecules
were treated classically using the CHARMM27 force field. Since the QMMM boundary
cuts across covalent bonds, we applied the single link atom procedure [89] to satisfy the
valences of broken bonds in the QM region. The electrostatic interactions between the
quantum region and the classical atoms belonging to groups at the QMMM boundary
were discarded as this choice has been shown to enhance the accuracy in the resulting
energies and geometries [71]. We have extensively explored this choice of the QMMM
region (including sensitivity to the size of the QM region, and the functional/basis set
combination) in our prior studies of closely related systems [203, 201, 202]; others have
validated the choice of the link atom [71]. Non-bonded van der Waals (VDW)
interactions were treated by applying a switching function at 10 Å and truncating the
VDW potential energy smoothly at a cutoff distance of 12 Å. The forces in the quantum
region were calculated on-the-fly, assuming that the system moves on the BornOppenheimer surface defined by the QMMM Hamiltonian. The system was first
subjected to 1200 steps of the adopted basis Newton-Raphson (ABNR) minimization and
subsequently QMMM MD simulations were performed during which the systems were
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first heated to 300 K and then subjected to constant temperature of 300 K dynamics using
a Langevin thermostat for 10 ps and a standard 1 fs time step of integration.

2.2.6 Catalytic Reaction Pathways
The exact reaction coordinate is complex and multi (high) dimensional and a quantitative
estimate of the free energy landscape can only be obtained using efficient long-time
sampling approaches [26, 38, 56, 79, 208], which remain prohibitively expensive for
QMMM applications due to large computational cost. Although we believe that the true
reaction coordinate is complex, in the spirit of the a recent study [212], we described the
reaction pathways in terms of several simple reaction coordinates, . For mechanisms of
phosphoryl transfer through associative mechanism,  includes the reactive distance
tyrosine O- ATP P, tyrosine O- ATP O2/3, and ATP P- ATP O2/3 distances. For
mechanisms of phosphoryl transfer through dissociative mechanism, in addition to the
three distances,  includes the coordinate for proton abstraction, namely tyrosine OHD830:O2. In order to drive the system along a reaction coordinate, we performed
restrained minimization as well as restrained sampling simulations using the QMMM
Hamiltonian along  by augmenting the Hamiltonian with a potential bias term
(1/2)K(||-0)2; here K is the effective spring constant (ranging between 10 and 30
kcal/mol/Å2) and 0 are reference values for sampling in different windows of .
Complete pathways were assembled by varying the offset distances 0 in increments of
0.05 Ǻ, where the positive and negative increments represent the directionality of the
energy scan. The reaction paths were computed by energy-minimizations in the presence
of restraints and recalculating the single-point energies in the absence of the constraints.
36

For our choice of the increments of 0, calculations performed in forward and reverse
directions satisfied path reversibility in configurations as well as energy values.
Following the energy scans, constant temperature restrained dynamics runs of 300 fs-1ps
for each choice of 0 was also performed to ensure that the reaction path was robust to
thermal fluctuations.

2.3 Results
2.3.1 Tyrosyl-Peptide Substrate Recognition by EGFR TKD
Following the computational protocols described above, 500 bound conformations were
predicted using ensemble docking protocol for binding of EGFR TKD to a seven-residue
native EGFR peptide with P0 corresponding to autophosphorylation site Y1068
(VPEYINQ). Since a large number of the resulting structures showed peptide
conformations in which the tyrosine residue was far from the active site, we constructed a
histogram of D: the distance between the tyrosyl-oxygen and the O2 oxygen of the
conserved catalytic aspartic acid residue (D813), see Figure 2.3A, and only considered
those conformations with D < 6 Å; this choice for the cut-off is intended to cover
situations where the hydroxyl group of the peptide forms a hydrogen bond with O2 of
D813, either directly, or through a water mediated interaction. In addition, conformations
in which the peptide substrate overlaps with the position of ATP (quantified using the bisubstrate conformation in the PDBID:2GS6 structure) were further discarded. Thus,
among the 500 predicted conformations, 18 structures of the TKD-substrate complex
satisfied our constraints, which were categorized into 5 clusters based on root-meansquared deviations (RMSD) of the backbone heavy atoms.
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Table 2.1 Rescoring of the top five predicted peptide conformations predicted by ensemble docking
(showed in Figure 2.3B) using MMPBSA based on 1-ns MD simulation. The RMSD (Å) is calculated
between the backbone atoms of the central five residue of the modeled peptide to the backbone atoms of
the five residue peptide portion of the bi-substrate in structure 2GS6.The unit of energy is Kcal/mol.

Conf.

RMSD

1

-157.4

153.3

-7.7

5.2

4.2

-2.4

5.45

2

-131.4

121.9

-7.5

5.5

4.3

-7.2

5.09

3

-134.4

109.4

-6.5

4.9

4.3

-22.2

2.72

4

-206.3

197.4

-7.9

5.4

4.2

-7.3

5.97

5

-107.5

103.7

-7.3

5.2

4.3

-1.6

3.92

The five conformations with the lowest score in each cluster are depicted in Figure 2.3B,
along with the bi-substrate conformation from the PDBID:2GS6 structure. The computed
MMPBSA binding free energies Gs of the five conformations are provided in Table 2.1;
as expected, the binding free energy is dominated by the difference between the
unfavorable polar solvation and the favorable molecular mechanics terms. Interestingly,
the conformation 3, which corresponds to the lowest MMPBSA score, also aligns most
closely to the bi-substrate conformation as shown in Figure 2.3B and Table 2.1.

38

Figure 2.3 Results of docking peptide Y1068 to EGFR TKD. A) Histogram of the distance between the
oxygen in hydroxyl group of the tyrosine and the oxygen atom in the carboxylate group of the D813 of all
the 500 predicted conformations by ensemble docking. Conformations with this distance less than 6 Å were
clustered into 5 clusters based on their backbone RMSD. B) Five predicted peptide clusters of Y1068
bound conformation generated by ensemble docking which satisfied the distance criteria in A. The bisubstrate peptide binding pocked are shown as the back surface area for comparison. All the five
conformations were re-ranked using MMPBSA, shown in Table 2.1. C) The bound conformation of peptide
Y1068 to EGFRTK in the presence of ATP and two MG2+ ions after 10 ns MD equilibrium. ATP are
depicted in red, MG2+ in green, peptide in blue and residues in EGFR TKD which are interacted with the
peptide in yellow. D) A close look of main interactions between the peptide and kinase: Y(P0) hydrogenbonded with D813; E(P-1) formed a salt bridge interaction with residue K855; hydrophobic residue I(P+1)
interacted with a hydrophobic surface in EGFR TKD consisted of residue V852-P853-I854-W856. All the
hydrophobic residues are depicted as transparent surface to show the interaction.

A 9-ns MD simulation performed using conformation 3 in the presence of ATP and two
Mg2+ ions reached steady state after 3 ns (Figure 2.4). The peptide backbone is stable
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during the entire simulation as monitored by the backbone RMSD relative to the initial
conformation (Figure 2.4). Therefore our predicted substrate conformation emerges to be
in close alignment with the bi-substrate structure in PDBID:2GS6 structure as shown in
Figure 2.3B. The side-chain residues, however, adjust conformations to result in stable
hydrogen bonds and hydrophobic interactions in the final predicted bound structure of the
ternary complex (EGFR TKD/tyrosyl-substrate/ATP) as shown in Figure 2.3C&D.

Figure 2.4 Evolution of RMSD and key distances for 10 ns MD simulation. The color schemes are: the
RMSD calculated based the backbone atoms of the central 5 residue of the peptide conformation to the
initial conformation (red); the distance between D813:O2 and Y(P0):Oη (green); the distance between
Y(P0):Oη and ATP:P (purple); and the salt bridge distance between K855 and E(p-1) (light blue).

The predicted conformation (Figure 2.3C&D) provides new insights into the substrate
recognition mechanism of EGFR TKD: (1) with respect to the P0-tyrosine, the Cterminal region of the peptide is anchored into a binding pocket formed by residues in the
C-terminal region of EGFR activation loop, and the N-terminal of the peptide extends to
the front of the C-terminal lobe of EGFR TKD (Figure 2.3C); (2) The hydroxyl oxygen
of the P0 tyrosine is 2.9 Å away from the O2 oxygen atom of residue D813, within a
hydrogen bond distance (Figure 2.3D); (3) the P-1 glutamic acid residue forms a salt40

bridge with a highly conserved lysine residue (K855); and (4) the isoleucine in P+1
position situates in a hydrophobic pocket formed by Val852, Pro853, Ile854 and Trp856 (
Figure 2.3D).

Figure 2.5 Results of docking peptide Y1173 to EGFR TKD. A) Six predicted peptide clusters of Y1173
bound conformation generated by ensemble docking which satisfied the distance criteria in Figure 2.3A.
The bi-substrate peptide binding pocked are shown as the back surface area for comparison. All the 6
conformations were re-ranked using MMPBSA, shown in Table 2.2. B) A close look of main interactions
between the peptide and kinase: Y(P0) hydrogen-bonded with D813; E(P-1) formed a salt bridge
interaction with residue K855; hydrophobic residue L(P+1) interacted with a hydrophobic surface in EGFR
TKD consisted of residue V852-P853-I854-W856. All the hydrophobic residues are depicted as transparent
surface to show the interaction.

To further validate the robustness of this predicted mode of tyrosyl-substrate interaction,
we also predicted the bound conformation of a different EGFR-native peptide sequence
(NAEYLRV) derived from the auto-phosphorylation site Y1173 of EGFR (shown in
Figure 2.5 and Table 2.2). The conformation predicted for Y1173 is very similar to that
for Y1068 (Figure 2.5B). In particular, the hydrogen bond between the hydroxyl of
tyrosine and D813, the salt-bridge between E(P-1) and K855, and the hydrophobic
contact between L(P+1) and VAL852-Pro853-Ile854 are all preserved.
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Table 2.2 Rescoring of the top six predicted peptide conformations predicted by ensemble docking ( Figure
2.5) using MMPBSA based on 1-ns MD simulation. The RMSD (Å) is calculated between the backbone
atoms of the central five residues of the modeled peptide to the backbone atoms of the five residues in the
peptide portion of the bi-substrate in structure 2GS6. The unit of energy terms is Kcal/mol.

Conf.

RMSD

1

-436.5

394.6

-8.0

5.9

4.5

-39.4

9.6

2

-238.0

217.1

-6.9

4.7

4.3

-18.8

10.0

3

-243.8

226.2

-8.1

5.4

4.3

-16.1

7.9

4

-114.2

111.8

-7.4

5.1

3.9

-0.7

10.6

5

-297.0

241.3

-7.1

5.3

4.7

-52.8

3.6

6

-250.1

228.5

-8.0

5.4

4.3

-19.9

9.7

2.3.2 Pre-Catalytic Conformational Landscape Orchestrates Multiple
Reaction Channels

Figure 2.6 Pre-Catalytic Conformational Landscape along the the nucleophilic attack distance a.

During the course of the MD simulation of the ternary complex, the conformational
equilibration of ATP and the two Mg2+ ions relative to the substrate tyrosine resulted in
small rearrangements of the phosphate tail of ATP within the active site. Hence, we chose
to explore the free energy landscape for the pre-organization of the nucleophilic attack
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distance a (Y(P0):Oη - ATP:P distance) as this distance is most relevant to catalysis and
most sensitive to the phosphate tail conformation (Figure 2.6). In conformation 1,
obtained from energy minimization of our model structure, a  4 Ǻ. However, in the
course of umbrella sampling, the system settles into another metastable state with a <3 Ǻ
(conformation 2), surpassing a nominal free energy barrier of 3.5 kBT (2 Kcal/mol). This
subtle pre-catalytic conformational transition corresponds to a conformational
rearrangement of -phosphate of ATP (compare snapshots). An analysis of conformations
within the window corresponding to conformation 2 revealed that the proton of the
tyrosine-hydroxyl (Hη) is primed for transfer to two possible positions owing to two
mutually exclusive hydrogen bonds: (1) hydrogen bonded to O2 oxygen of D813
(indicated by a small value of I), and (2) hydrogen bonded to the O1 oxygen of ATP
(indicated by a small value of II).

Figure 2.7 Normalized histograms representing the distributions of values for the distances between the
proton of the substrate tyrosine hydroxyl and (A) the O2 oxygen of D813 in EGFR or equivalent in ErbB3
(I) or (B) the O1 oxygen of ATP (II) recorded in our simulations of the ground state (reactant)
dynamics.
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We hypothesize that the bimodal distributions of I and II values represented in the
normalized histograms in Figure 2.7 serve to select either of two competing catalytic
routes, labeled as pathways I and II in Figure 2.8 for proton transfer and concomitant
phosphoryl transfer. We explore this hypothesis further by investigating the possible
mechanisms of phosphoryl transfer in EGFR TKD following the protocols for QM/MM
minimization and QM/MM MD simulations. Our simulations (see Figure 2.9) reveal that
the phosphoryl transfer via pathway I in which the proton is abstracted through the
catalytic aspartic acid residue can occur via both the dissociative and associative
mechanisms, while pathway II supports only the associative mechanism. For pathway I,
(highlighted red in Figure 2.8), the phosphoryl transfer step occurs through either a
dissociative mechanism (Figure 2.9A), or an associative mechanism (see Figure 2.9B),
and proceeds concomitant with migration of the proton from the hydroxyl group of the
tyrosine substrate to the O2 oxygen of D813. In the dissociative reaction channel, the
sum of the nucleophilic attack distance a (between Y-OH and ATP P) and the bondcleavage distance c (between ATP P and ATP O2/3) in the transition state is greater
than the corresponding sum in the reactant and product states; this scenario is reflected in
Figure 2.9A where the a+c values for transition state (TS) are greater than those for
Rectant (R) or Product (P) states, i.e., the TS region lies above the line joining the R and
P states in the a versus c plot. In contrast, a nucleophilic attack through an associative
mechanism is evident in Figure 2.9B where the a+c values for TS are smaller than
those for R or P, i.e., TS lies below the line joining the R and P in the a versus c plot.
Pathway II (highlighted blue in Figure 2.8) is characterized by the migration of the proton
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from the hydroxyl group of the tyrosine substrate to the O1 oxygen of ATP and the
subsequent transfer of the proton to the O3 atom of ATP. The phosphoryl transfer takes
place concomitant with the proton transfer steps but only through an associative
mechanism, see Figure 2.9C; interestingly, for this channel, our attempts to drive the
system through a dissociative mechanism yielded an associative mechanism with the O2
atom of ATP playing the surrogate (as the leaving group) to the O3 atom of ATP.

Figure 2.8 Proposed schematic of pathway for phosphoryl-transfer in EGFR-TKD. Mg2+ ions and the
catalytic aspartates (D831) are marked. Two potential pathways for proton migration (concomitant with
phosphoryl-transfer) are shown. Pathway I (red) involves proton abstraction from the substrate tyrosine –
OH group by D813 of EGFR, and pathway II (green) involves proton migration to the O1 oxygen of ATP.
I and II denote distances between the proton of the substrate tyrosine hydroxyl and either the O2
oxygen of D813 (I) or the O1 oxygen of ATP (II). The nucleophilic attack distance, a (distance
between the tyrosine oxygen and the ATP P) and the bond cleavage distance, c (distance between the
ATP P and ATP O2/3) are also noted.

45

Figure 2.9 QM/MM results for proposed pathways. (A)&(D): Pathway I and dissociative; (B)&(E):
Pathway I and associative; and (C)&(F): Pathway II and associative. R = reactant; P = product; and TS =
transition state characterized by a trigonal bipyramidal geometry about P . (A-C) Distributions of values for
the nucleophilic attack distance, a (distance between the tyrosine oxygen and the ATP P) and the bond
cleavage distance, c (distance between the ATP P and ATP O2/3) along the reaction pathways. (D-F)
Energy changes along the reaction pathways in QM/MM simulations for the noted mechanisms.

In Figure 2.9(D-F), we depict the computed energy changes along the reaction pathways
in active EGFR TKD, which suggest that for EGFR, the dissociative mechanism of
phosphoryl transfer through pathway I corresponds to the lowest activation energy, Ea=16
kcal/mol (Figure 2.9D), while energy profiles for the associative mechanisms through
pathways I and II yield barriers of 24 kcal/mol (Figure 2.9E) and 26 kcal/mol (Figure
2.9F), respectively.

2.4 Discussion
Crystal structures of multiple TKDs have already been solved, which has led to important
insights in understanding the kinase function. However, most of these crystal structures
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are solved in the presence of ATP analogs and small molecule inhibitors. Due to the
relatively low binding affinity of the interaction between TKD and peptide substrates,
crystallization of TKD-peptide substrate complexes is still a challenge using experimental
techniques. In this chapter, we suggest that a rich landscape exists for the binding of
tyrosyl-substrate and subsequent pre-catalytic and catalytic events in the ternary complex
of EGFR TKD/ATP/tyrosyl-substrate, from which we outline new molecular rules, which
may, in-part, contribute to specificity in phosphorylation reactions.
Our ensemble molecular docking protocol is successful in predicting bound
conformations of a 7-residue peptide sequence derived from the C-terminal tail region of
EGFR to EGFR TKD, with predicted bound conformation very similar to that found in a
crystal structure of a bi-substrate analog co-crystalized with EGFR TKD [289] (PDBID:
2GS6). In our predicted complex, the aspartic residue D813 forms a hydrogen bond with
the hydroxyl oxygen the P0 tyrosine of the peptide substrate. The aspartic residue has
been shown to hydrogen-bond with the hydroxyl group of serine/threonine/tyrosine in
other kinase systems [119, 235, 292]. In the only existing EGFR TKD/bi-substrate analog
structure (i.e. PDBID: 2GS6), the distance between the aniline nitrogen and the O1/2
oxygen of D813 is 6.37 Å, which makes it difficult to ascribe a role for the aspartic
residue. The conformation in our modeled ternary complex clearly places the hydroxyl
oxygen of the P0 tyrosine 2.9 Å away from the O2 oxygen atom D813, i.e., within
hydrogen bonding distance, which is consistent with the conceived role of D813 as a
facilitator of proton abstraction.
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Moreover, it has been suggested that protein tyrosine kinase (including EGFR) select
substrates with glutamic acid at the P-1 position and large hydrophobic amino acids at the
P+1 position [85, 86, 118, 123, 149, 245]. Our predicted peptide bound ternary complex
suggests that a highly conserved region, corresponding to Val852-Pro853-Ile854-Lys855Trp856 in EGFR TKD is essential for substrate binding: Lys855 forms a salt bridge with
the highly preferred glutamic acid residue at the P-1 site, and the hydrophobic pocket
formed by Val852, Pro853, Ile854 and Trp856 serves to anchor a large hydrophobic
residue at P+1 position. This observed binding mode for our top-ranked configuration is
consistent with the hypothesis that the substrate binding surface formed through
hydrophobic contacts and hydrogen bonds help orient the tyrosine residue for catalysis
[149]. Collectively, this extended region, i.e. Val852-Pro853-Ile854-Lys855-Trp856 in
EGFR, has been identified as a highly conserved motif in the protein tyrosine kinase
family [28], which further adds significance to our predicted conformation for the ternary
complex. This allows us to conclude that a conserved binding surface on the kinase
sandwiching the P0-tyrosine and making hydrophobic contact to the P+1 and hydrogen
bond with P-1 residues, respectively, helps orient the tyrosine residue for catalysis [149].
Interestingly, the corresponding motif in serine/theronine kinase, with a sequence of
Gly200-Thr201-Pro202-Glu203-Tyr204 in PKA, has been named as P+1 binding pocket
and shown to be critical for substrate specificity [35, 104, 149]. In this case, the glutamic
acid residue (E203) in this motif has been proposed to interact with preferred positively
charged residues of the N-terminal site in PKA substrates [149], and residues Gly200,
Pro 202, Thr201 and Tyr204 favor a hydrophobic residue in the P+1 position [261].
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Two of the main points of contention in kinase-catalyzed phosphoryl transfer reactions
are whether the phosphoryl-transfer reaction occurs through an associative or a
dissociative mechanism (39, 41-44) and whether the conserved aspartic (D813 in EGFR)
functions as an acceptor for proton transfer from the hydroxyl group of the substrate.
With the predicted peptide bound conformation, we were able to build the ternary
structure of EGFR TKD and peptide with ATP and Mg2+ ions, and investigate the
mechanistic details of EGFR TKD catalytic reaction mechanism using QM/MM
simulations. Based on a pre-catalytic energy landscape of -phosphate of ATP we
identify two alternative preferred proton positions of the tyrosine hydroxyl based on
which we hypothesize two possible pathways: Pathway I involves proton abstraction
from the substrate tyrosine hydroxyl group by D813 of EGFR, and pathway II involves
proton migration to the O1 oxygen of ATP. Indeed, our QM/MM simulations support
both pathways, with the phosphoryl transfer via pathway I sustained via both dissociative
and associative mechanisms, while that via pathway II sustained by just the associative
mechanism. The dissociative mechanism through pathway I has the most favorable
energy barrier of 16 kcal/mol, while energy profiles for the associative mechanisms
through pathways I and II each yield barriers of 24 kcal/mol. Combined with the precatalytic reaction energy barrier, our estimate for the net energy barrier Ebarrier for
activation through the most favorable reaction channel (i.e. for pathway I through
dissociative mechanism) in the active EGFR TKD is 16+2=18 kcal/mol. This value
compares favorably with the experimental value for the free energy barrier for EGF
activated

receptor

system

in

the

cellular

context

for

which

Gbarrier=kBTln[kBT/(kcath)]=18.5 kcal/mol was estimated from the reported kcat of 17.4
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min-1 by Gibbes-Johnson et. al. [84]. Our estimate for the net energy barrier Ebarrier for
activation through pathway II for active EGFR TKD is 24+2=26 kcal/mol. This translates
to a kcat of 10-6 s-1 or a reduction by at least a factor 10-6 relative to the experimental kcat
of EGF activated receptor or a factor of 10-5 relative to experimental kcat in the absence of
EGF [85, 185]. The reduction in kcat manifests itself as little or very weak residual
activity through pathway II, which is consistent with recent experiments [147, 244].
Given that the protonation states of titratable side-chains in the active site can have
considerable effect on the stability of the ground state as well as on the energies of the
reaction landscape, we explored the different protonation states of the conserved catalytic
residue D813 in EGFR. Multiple protonation states of the conserved catalytic residue
(D831 of the DFG motif) was not considered because the location is relatively remote
from the atoms involved in the catalytic reaction pathway. Although recent studies of the
Abl kinase have reported that the protonation state of this residue is important in the
flipping of the DFG motif toward the active conformation [257]. Such a flip for EGFR is
already facilitated, even in the unprotonated state for D831, by kinase dimerization [162].
For the D813-protonated system, the phosphoryl transfer step occurs through an
associative mechanism and proceeds with the simultaneous migration of the proton from
the hydroxyl group of the tyrosine substrate to the O1 oxygen of D813 and the migration
of H2 of the protonated O2 oxygen of D813 to O3 atom of ATP (data not shown). Our
attempts to drive the system through a dissociative mechanism yielded an associative
mechanism with the O2 atom of ATP playing the surrogate (as the leaving group) to the
O3 atom of ATP.
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Figure 2.10 Possible catalytic reaction pathway for ErbB3 modeled by QM/MM simulation.

ErbB3/HER3 is another member of the human epidermal growth factor receptor
(EGFR/HER) or ErbB receptor tyrosine kinase family. ErbB3 is considered to be an
inactive pseudokinase because it lacks several key conserved (and catalytically
important) kinase domain residues – including the catalytic base aspartate. Very recently,
our collaborator, Dr. Mark Lemmon‟s laboratory, reported that despite this residue
alteration, the kinase domain of ErbB3 retains phosphoryl-transferase activity, as
evidenced by trans-autophosphorylation of the purified ErbB3 intracellular region [237].
Kinase activity appears to be ~1000-fold weaker than that seen for EGFR. Moreover,
they showed that the ErbB3 kinase domain binds ATP with a KD of approximately
1.1 M, similar to that seen for known active kinases. A crystal structure showed that the
overall structure of ErbB3-TKD665-1001 closely resembles the inactive conformations of
the EGFR, ErbB4, and Src kinases [198, 287]. The structure also clearly showed the
electron density for both AMP-PNP and Mg2+, which are similarly positioned as in the
EGFR TKD structures.
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To address this observation, we hypothesized that the weak kinase activity of ErbB3
might utilize a mechanism distinct from that seen in other kinases, and might be carried
out by the „inactive-like‟ state. We therefore undertook quantum mechanics molecular
mechanics (QM/MM) simulations to delineate the energy landscape of phosphoryltransfer from ATP to a substrate tyrosine catalyzed by the ErbB3 structure, and compared
the outcomes with those seen in parallel computational studies of EGFR. Due to the
presence of an asparagine (rather than aspartate) at N815, pathway I proposed for EGFR
is not sustainable in ErbB3. However, like active EGFR TKD, the proton migrates to the
O1 oxygen of ATP, through pathway II in Figure 2.10. Phosphoryl-transfer concomitant
with this pathway can be catalyzed by ErbB3 in the inactive-like conformation, although
it is predicted to be several orders of magnitude slower (estimated Ea is 24 kcal/mol) than
the most favorable reaction channel in EGFR (i.e. for pathway I through a dissociative
mechanism) – consistent with experimental observations.
Indeed, a D813A-mutated variant of EGFR variant has been reported to retain its ability
to promote EGF-dependent DNA synthesis and MAP kinase activation despite exhibiting
greatly reduced receptor autophosphorylation [65]. A low level of autophosphorylation in
D813A-mutated EGFR, similar to that shown for ErbB3, may therefore be sufficient to
mediate certain key aspects of its signaling.
ErbB3 signaling is important in development of resistance of NSCLC to the EGFR
inhibitor gefitinib through amplification of the gene for Met [80], the hepatocyte growth
factor receptor. ErbB3 also plays a key role in the ability of ErbB2-overexpressing cells
to escape growth inhibition by the EGFR/ErbB2 dual-specific kinase inhibitor lapatinib
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[229]. Our data suggest that evaluating the signaling importance of ErbB3‟s weak kinase
activity is also worthwhile, and could represent a valuable therapeutic target. Indeed,
ErbB3 autophosphorylation in vitro is not inhibited by lapatinib or by the EGFR
inhibitors gefitinib or erlotinib, leaving open the possibility that ErbB3 kinase activity
promotes resistance to growth inhibition by EGFR/ErbB2-targeted drugs. If this is the
case, selective inhibition of the ErbB3 kinase could be an additional effective therapeutic
strategy.
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Chapter 3 Interaction

of

Erlotinib

to

Different

Conformational States of the Epidermal Growth Factor
Receptor Tyrosine Kinase Domain (EGFR TKD)
3.1 Introduction
EGFR and other ErbB-family receptor tyrosine kinases have been associated with the
development, progression and aggressiveness of a number of malignancies [173, 233].
The EGFR kinase has long been recognized as a potential drug target. Small molecule
receptor tyrosine kinase inhibitors (TKI) for EGFR TKD are of significant interest as
cancer therapeutic drugs [61]. Erlotinib and gefitinib are two EGFR TKD inhibitors
which have been approved for the treatment of advanced Non-small cell lung cancer
(NSCLC) [8, 242]. These two drugs caused a dramatic response in a sub-group of
patients in clinical trials. A class of mutations, including the point mutation in the
activation loop (L834R), have been reported correlate highly with favorable clinical
responses of patients to gefitinib and erlotinib [48, 164, 186]. The discovery of these
mutations and their correlation with the drug response has fueled an intense interest in
studies of the oncogenic effects and drug binding properties of these mutations. Although
a lot effort has been made, a mechanistic basis for such a correlation remains unclear.
While many factors may contribute to drug response [80, 101, 244], a basic question to
be answered is whether the mutations will directly affect the drug binding. Available
crystal structures have shown that L834R EGFR TKD shares a very similar fold with the
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wildtype kinase and gefitinib was shown to be bound very similarly to wildtype and
L834R mutatant EGFR TKD [77, 284]. Erlotinib complexed with wildtype EGFR TKD
[248, 284] shows a very similar binding mode to that of the gefinitb EGFR TKD. Despite
the similarity in binding modes, several groups have reported varying results for the
binding affinities of gefitinib and erlotinib to EGFR TKD (shown in Table 3.1), thereby
creating some controversy over the notion that the binding mechanism is a common one.
Although two separate studies [83, 101] reported no overall effect of the mutations on
drug binding, other studies have claimed an increase in binding affinity for the drug in the
L834R mutant (relative to wildtype) [48, 284].
Table 3.1 Binding affinities reported for Erlotinib and Gefitinib binding to EGFR TKD.

EGFR

Ki (nM)
Erlotinib

Gefitinib

WT

0.67[83]

17.5[48]

0.9[83]

0.19[101]

53.5[284]

L834R

0.97[83]

6.26[48]

1.3[83]

0.20[101]

2.6[284]

Like many other kinases, two EGFR TKD conformations, namely active and inactive,
have been captured in crystal structures [248, 276, 284, 288]. Both erlotinib and gefitinib
were solved in complex with active EGFR TKD [248, 284], while another inhibitor,
lapatinib, was crystallized in an inactive EGFR TKD conformation. Such structural
studies have lead to a prevailing conclusion that erlotinib/gefitinib are specific to active
EGFR TKD form whereas lapatinib preferentially binds to the inactive conformation.
L834R kinase structure has been found to adopt a similar conformation to the active
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wildtype structure. As the L834 residue lies in the helical turn of the activation loop in
the inactive state of the kinase, it has been proposed that mutation L834R will destabilize
the inactive structure by disrupting the hydrophobic interaction which stabilizes the
relatively displaced αC-helix in the inactive state, thereby providing an activating
stimulus. As a result of the assumed preference of active form of EGFR TKD in L834R
system, it has been proposed that a tighter binding of erlotinib and gefitinib would result
in the mutant TKD. Moreover, very recently, a new experimental study has shown that
the relative selectivity of erlotinib to the active-state EGFR TKD is only 5-10 fold higher
than that to inactive-state EGFR TKD[199], which raises the possibility of crossover
binding of these inhibitors to inactive TKD conformations. To test the hypothesis that
L834R affects inhibitor binding by altering the equilibrium between active and inactive
states of EGFR TKD, a detailed study of the binding mechanism of erlotinib/gefitinib to
wildtype and L834R TKD is necessary.
In this chapter , we computationally docked the erlotinib to L834R mutated EGFR TKD
using an induced fit docking protocol, and then compared the binding of erlotinib with
wildtype and L834R mutated TKD using molecular dynamics. We also employed free
energy perturbation to further elucidate the free energy difference between wildtype and
L834R systems. Our results suggested that erlotinib binds in a similar fashion to wildtype
and mutated kinase systems in the active form. We further compared the erlotinib binding
with both active and inactive EGFR TKD and proposed that erlotinib is capable of
binding to both forms with similar binding efficacy. Our simulation results illuminate the
complexity of inhibitor binding in EGFR TKD and highlight the importance of targeting
erlotinib and other inhibitors to different conformations of the kinase.
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3.2 Methods and Materials
3.2.1 System preparation and molecular docking
Protein structures were taken from the Protein Data Bank: the active conformation of the
wildtype EGFR TKD was modeled on 1M17 [248] and 2ITX [284] and the L834R model
was built using the 2ITV structure [284]. The inactive EGFR TKD was modeled based on
the 2GS7 [288] and 1XKK [276] structures. Initial erlotinib conformation was also taken
from the 1M17 structure. Protein and ligand conformations were prepared using the
protein preparation wizard and the “LigPrep” tools available within the Schrödinger
computational chemistry package[224]. All simulations using Schrodinger were
performed with the OPLS force field[137] . In particular, the docking simulations were
performed using Schrödinger‟s Induced Fit Docking (IFD) package [236]. With the
induced fit docking protocol, the ligand was first docked to a rigid protein conformation
using Glide XP [98]; for the resulting top 20 complex conformations, the protein side
chains residues within 5.0 Å of the ligand poses were subject to conformational search
and minimization using the prime structure prediction method [129, 130]; finally the
ligand was re-docked to the 20 new receptor conformations. Therefore, this docking
protocol includes possible binding modes of ligands as well as the associated
conformational reconfiguration within the receptor active site.

3.2.2 Parameterization of erlotinib
The resulting conformations from induced fit docking were analyzed using molecular
dynamics simulations and the CHARMM27 forcefield [93], which consists of the
following terms:
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, where,
,

,

,

,

are the bond, angle and dihedral force constants; the

represent the equilibrium value of bond, angle and dihedral;

and  ij are,

respectively, the distance between atoms i and j at which the LJ potential is zero and the
depth of the LJ potential well for the same pair of atoms; D is the effective dielectric
constant and qi is the partial atomic charge on atom. Since the CHARMM27 force-field
did not contain the parameters for erlotinib, all these parameters had to be defined for
each atom type of erlotinib (see Figure 3.1).
The atom types describing the erlotinib molecule are shown in Figure 3.1. 9 new atom
types were added to the CHARMM topology file. Initial partial atomic charges ( qi ) were
calculated using CHarges from ELectrostatic Potentials using a Grid based method
(CHELPG) [33] in the ab-initio electronic structure package GAUSSIAN, by fitting the
molecular mechanics-derived electrostatic potential to that obtained quantum
mechanically. The van der Waals constants (

and  ij ) were transferred from existing

CHARMM parameters and were not modified during refinement as their values depend
mostly on atomic properties and are assumed to be transferable to the molecular
environment. The equilibrium constants ( b0 ,  0 ) were obtained from optimized structures
of the small molecules based on the crystal conformation [248] using geometry
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optimization in ab-initio calculations, and were also not changed during refinement. An
initial guess, based on an analogy with other existing CHARMM parameters is made for
all missing intermolecular force field constants K b , K , K  , and the equilibrium
constants for the dihedral terms, namely, n , and  . In particular, for the carbon-carbon
triple bond, we first performed ab-initio potential energy surface scan along the bond
length, then use parabolic potential function to fit the potential surface and get initial
estimation of this bond constant.
HA
CC3
CC3
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CA
CA
CA

HP

HP
CA
CA

H

CA

NAQ3

HP
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CAQ2
NAQ2
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CAQ3

OS
CAQ4

HA
HA

CT2
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CT3
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HA

CAQ1
HP

NAQ1

CAQ3

CAQ4
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CT2
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CT2
HA

HA
HP

HA
CT3
HA

HA

Figure 3.1 Atom type defined for erlotinib. New atom types are shown in blue.

Partial atomic charges ( qi ) were adjusted to reproduce interaction energy and geometry
of H-bond donor/acceptor atoms in the inhibitor compound with water molecules (Figure
3.2). The hydrogen bonded complexes shown in the figure were individually optimized
via ab-initio calculations using the 6-31G* basis set with fixed monomer geometries. The
partial atomic charges in CHARMM are manually adjusted to reproduce the ab-initio
results for the geometry and energy. Following the strategy for generating the CHARMM
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force field [93, 166, 189] , the ab-initio interaction energies are scaled by 1.16 and the
distances are offset by -0.2 Å.
H33
O3
N1H
N1

H32
H8

O2
H21

H22

C6
N3
C19

H19

C8
C7

C9

C18
N2
H11

C13
C17
H17

O1
H12

Figure 3.2 Water interactions used to refine the force field.

The force constants

,

and,

were refined by reproducing the vibrational

eigenvalues and eigenvectors from ab-initio calculations following the procedure
employed by Viana et. al. [263], which ensured that both vibrational frequencies and
vibrational modes (defined by eigenvectors) calculated from CHARMM and those from
ab-initio methods match closely. In the algorithm, the current parameter set is used for
energy minimization and the calculation of normal modes iC and  ic (eigenvalues and
eigenvectors) with CHARMM. Each of the modes is projected to the eigenvector sets  Gj
(the corresponding quantity calculated from Gaussian) and a best projection, (mode i in
CHARMM projecting to mode j max in GAUSSIAN), is obtained according to two
criteria: (1) there is a one-to-one correspondence of the two-sets of eigenvectors, and (2)

 max
i

1
j

( ic   Gj )

is a minimum. Then, the penalty function value is calculated by:
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3 N 6



  (
i 1

i

C
i

  Gj max ) 2

3N  6

, i 

1
max j ( ic   Gj )

. In the ideal case, iC   Gj max ic   Gj   ij

, which implies that the CHARMM parameter set can perfectly reproduce the frequency
spectrum from GAUSSIAN.
For the dihedral potential surface fitting, relaxed potential surface scan for key dihedral
angle (C4-C4-N1-C6) is performed by both CHARMM and GAUSSIAN and defined as

DC , DG and the penalty function is defined as  

NGRID


i 1

( DiC  DiG )2

.

Figure 3.3 Optimization of the merit function based on a genetic algorithm.

An automated procedure using a genetic algorithm (GA) [178] is developed for the
refinement of the intermolecular force field constants and the dihedral potential energy
surfaces. The efficiency of the GA algorithm is showed in Figure 3.3 . We iteratively
repeat the procedure to refine 1) partial charges; 2) frequencies and eigenvectors; and 3)
the dihedral surface scan until reaching a force field with which, the target data – the
water interaction, the dihedral potential energy surface, and the vibrational normal modes
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– calculated by CHARMM matches well with the corresponding values calculated by
Gaussian.

Figure 3.4 Target data matching between electronic structure (Gaussian) and molecular mechanics
calculations (CHARMM). A: one-to-one correspondence of frequencies. The frequencies are matched
based on eigenvectors. B: dihedral scan.

An empirical parameter set for erlotinib optimized to be consistent with the CHARMM27
force field set (see Table 3.2 and Figure 3.4) was developed by following the procedure
described above. This parameter set was employed in molecular dynamics simulations.

3.2.3 Molecular dynamics simulations
The conformations resulting from induced fit docking were minimized and subsequently
equilibrated by performing molecular dynamics simulations. Each system was subjected
to a constant temperature and constant pressure molecular dynamics run at 300 K and 1
atm followed by a 10 ns constant temperature equilibration at 300K with periodic
boundaries enforced and long-range electrostatics taken into consideration.
Table 3.2 Water-erlotinib interactions and erlotinib dipole moment calculated by ab-initio (Gaussian) and
CHARMM. The ab-initio interaction energies in the table have been scaled by 1.16 (See text) and the
distances are scaled by -0.2 Å.
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Interaction Energies (Kcal/mol)
Hydrogen bond

Distances (Å)
GAUSSIA
CHARMM
N

GAUSSIAN

CHARMM

N2…HOH

-6.69

-6.61

1.93

1.91

N3…HOH_2

-5.33

-5.30

2.12

2.01

N1H…OHH_2

-6.52

-6.52

2.44

2.63

Dipole moment

GAUSSIAN

CHARMM

(Debye)

4.87

5.07

3.2.4 MMPBSA calculation
We employed MMPBSA [102, 117, 150, 153, 231, 253, 266] to calculate the absolute
binding free energy and compared it to the glide score. MMPBSA Energies of each
modeled complex conformation were calculated as the average of single point MMPBSA
energy of 500 snapshots taken from the 10 ns of the simulation. Waters and ions were
removed from the trajectory before calculation. The molecular mechanics energy, UMM,
was evaluated by averaging energies over all structures using an infinite cutoff for nonbonded interactions. The electrostatic contribution to the solvation free energy, W PB, was
calculated with Poisson-Boltzmann Solver in CHARMM [126]. The reference system
had a solvent dielectric of 1 and 0 M salt concentration and the solvated system had a
dielectric of 80.0 and 100 mM salt concentration. Non-polar contribution to solvation free
energy, WSA, was approximated with the suface area model WSA=[0.00542
kcal/mol/Å2]SASA +0.92 kcal/mol [215], where the molecular surface area (SA) was
estimated with a 1.4 Å slovent probe radius. Vibrational entropy changes were neglected.
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3.2.5 Free energy perturbation (FEP)
We designed a thermodynamic cycle shown in Figure 3.5 to directly calculate binding
free energy changes using FEP. To calculate the binding free energy change

,

we calculated the difference between the free energy changes caused by mutation in the
bound state (

) and the unbound state (

). The binding free energy change due to

the mutation is obtained as

.

Figure 3.5 Thermodynamic cycle for the calculation of binding free energy change of ligand/substrate due
to mutation

The free energy changes caused by the particular mutation in the bound state (
the unbound state (

) and

) were calculate by free energy perturbation (FEP) method [171,

204, 205] . The FEP procedure was performed using the alchemical method in NAMD
2.7b2 using the dual-topology paradigm. For each state (bound or unbound), we
performed FEP calculation in both the forward and backward direction to ensure
convergence and define an error bar. For each direction, the perturbation was divided into
72 windows (λ= 0, 10-6, 10-5, 10-4, 10-3, 10-2, 0.005, 0.01, 0.015, 0.02, 0.03-0.1 at an
interval of 0.01, 0.1-0.9 at an interval of 0.02, 0.9- 0.98 at an interval of 0.01, 0.098,
0.0985, 0.099, 0.995, 0.999, 0.9999, 0.99999, 0.999999, 1). In each window, the system
64

was equilibrated for 20 ps and run for another 100 ps for data collection. Larger window
sizes and longer simulations have also been tested and the current setup yields reasonable
convergence in the final binding affinity. To avoid the “end-point catastrophes”, a softcore potential was used to gradually scale the unbounded interaction potential. The
scaling of van der Waals (vdW) and electrostatic interactions were handled separately.
For appearing atoms, vdW interactions are linearly coupled to the simulation from λ=0
(fully decoupled) to λ=1 (fully coupled) and electrostatic interactions are coupled over
the range of λ=0.5 to λ=1. For vanishing atoms, the vdW interactions are linearly
decoupled from the simulation over the value range of 0 to 1, and the electrostatic
interactions are decreased gradually from λ=0 to λ=0.5.

3.3 Results
3.3.1 Erlotinib binds to wildtype and L834R with similar modes and
affinities.
The crystal structure of erlotinib bound to wildtype EGFR TKD was solved in 2002
[248]. As a control, we first docked erlotinib to two wildtype EGFR TKD conformations
using Glide: one from the exact crystal complex (1M17) [248] and another from a
crystallized EGFR TKD with the presence of ATP analog (2ITX) [284]. In both cases, we
predicted the compound in a very similar orientation compared to the crystal
conformation (Figure 3.6). The quinazoline moiety forms one hydrogen bond with
residue Met769 of the kinase and the distances between N2 of the quinazoline and the
amide nitrogen of Met769 are 2.9 Å in both the predicted structures, close to that in
crystal structure (2.7 Å). The acetylene moiety extends to the back of the ATP binding
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pocket, surrounded by the side chains of the Leu764, Lys721 and Thr766. Although the
“tails” of the compound in our predicted conformation do not overlapped with those in
the crystal structure, the differences are not significant, as the tails project into the solvent
and do not make significant contacts with the protein residues.

Figure 3.6 The docked conformation of erlotinib bound to wildtype (blue) and L834R mutant (orange)
EGFR TKD compared with the crystallized complex of erlotinib and wildtype EGFR TKD (green).

We then prepared the complex structure of erlotinib with L834R system by docking the
inhibitor to L834R EGFR TKD (PDBID: 2ITZ). The best predicted conformation is
shown to align very closely to that of the wildtype (Figure 3.6) with the „tails‟ projecting
into solvent and the aniline moiety binding in the pocket formed by Leu764, Lys721 and
Thr766. The distance between N1 of the quinazoline and the amide nitrogen of Met769 is
3.15 Å, which is within the hydrogen bonding distance.
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Figure 3.7 Monitoring of root mean squared deviation (RMSD) of erlotinib and key distances between
EGFRTKD, erlotinib as well as water molecules in a 10 ns molecular dynamics simulation. Data from the
first 2 ns (pre-equilibration) are not shown.

In both wildtype and L834R mutant systems, the erlotinib conformation is stable in the
predicted position during the entire course of the 10 ns simulation. The hydrogen bond
between quinazoline and Met769 in the wildtype and mutant system were found to
fluctuate around an average value of 3.17 Å for wildtype and 3.13 Å for L834R mutant
(Figure 3.7). The aniline moiety remains in the pocket of the Leu764, Lys721 and thr766
during the dynamics simulation while the two tails of the erlotinib are seen to be flexible
in both systems.
Table 3.3 Distances between donor and acceptor atoms in the water mediated hydrogen bond network (all
distances have a units of Å)

W1- W1- W1- W2- W2Distances W1Erlotinib T830 T766 W2 T766 Q767

W2Erlotinib

Wildtype

3.25

3.12

3.50

2.96 3.56

2.90

4.20

L834R

3.40

2.83

4.38

2.86 2.95

2.85

4.03
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Figure 3.8 Two typical water mediated networks in the erlotinib / EGFR TKD complex.

In the crystal structure (PDBID: 1M17), one bound water molecule is resolved, which is
described as bridging the gap between Thr766 and the quinazoline nitrogen atom (N3). In
our MD simulations, two water molecules were found to enter the (back) pocket for ATP
binding and formed a stable hydrogen bond network between erlotinib and residues
Thr830, Thr766 and Gln766 after the initial 2 ns of equilibration. The average distances
between donors and acceptors in the networks for both wildtype and L834R are described
in Table 3.3 and the fluctuations are depicted in Figure 3.7. We also depict two typical
hydrogen networks in Figure 3.8A&B. In both networks, the first water molecule (W1)
bridges the N3 atom of erlotinib, Thr830 and the second water molecule (W2) interacts
with Gln767. In network A, W2 interacts with Thr766 while in network B, W1 interacts
with Thr766. The two networks were found in both wildtype and L834R systems. While
they were seen to be equally favored in wildtype system, the L834R system showed a
preference for network A, which can explain the differences in the average values of W1Thr766 and W2-Thr766 distances in Table 3.3. A similar conclusion of two-water-
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mediated interactions between erlotinib and EGFR TKD has also been reported in an
earlier study involving a different force field [12].
Table 3.4 Binding affinities calculated by Glide, MMPBSA and FEP for wildtype and L834R system.

Glide Score

MMPBSA Score

FEP

(kcal/mol)

(kcal/mol)

(kcal/mol)

Wildtype

-9.34

-28.2

L834R

-9.35

-30.7

ΔΔG

-0.01

-2.5

0.831±1.158

To compare the binding affinities of erlotinib to wildtype and mutant EGFR TKD, we
provide the absolute binding energy calculated using Glide and MMPBSA in Table 3.4.
Both the Glide docking scores as well as the MMPBSA energies are very similar in
wildtype and L834R. We also report the difference in relative binding free energy
computed based on the thermodynamic cycle in Figure 3.5 and FEP calculations. In the
FEP calculation, the free energy difference between the wildtype and the L834R system
for the bound and unbound state were calculated in both forward and backward directions
of FEP integration in order to obtain a convergence measure. The cumulative free energy
differences are shown in Figure 3.9 and the resulting

values are 0.68 kcal/mol

and 0.98 kcal/mol in the forward and backward directions, respectively; thus, the FEP
calculations yield an average of 0.83±1.16 kcal/mol in the free energy difference between
the wildtype and the L834R systems.
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Figure 3.9 Cumulative free energy (kcal/mol) calculated for bound and unbound systems in both forward
and backward directions. .

3.3.2 Erlotinib interacts with the inactive EGFR TKD
It has been established that specific kinase inhibitors can target different forms of the
same enzyme [151, 217]. In EGFR TKD, erlotinib has been crystallized with active
wildtype EGFR TKD, based on which it is assumed widely that erlotinib is more
effective in inhibiting the activated EGFR kinase. To challenge this notionHere, we
explore the possibility for erlotinib to bind with the inactive EGFR TKD.

Figure 3.10 The docked erlotinib conformation to wildtype inactive EGFR TKD.
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The docked conformation of erlotinib to wildtype inactive EGFR TKD is shown in
Figure 3.10. The conformation is very similar to that presented in the active EGFR TKD,
with the same orientation and the critical hydrogen bond between N2 of erlotinib and
Met769. This conformation has also been verified to be stable in 10 ns MD simulations.
Besides the two water molecules present in the active kinase, there is a third water
molecule entering the back pocket to fill the void formed by Met742, Leu753, Thr766,
Thr830, Phe832 and Leu834, where the 3-fluobobenzyloxy group of the lapatinib
overlays in the crystal structure (PDBID: 1XKK). The erlotinib conformations (after 10
ns MD simulations) in both active and inactive wildtype EGFR TKD were aligned based
on EGFR TKD backbone, see Figure 3.11. Except for the additional water molecule,
erlotinib has a very similar binding mode in both kinase conformations. Morever, the
glide score for erlotinib binding to inactive TKD is 9.72 kcal/mol, which is very close to
that for the the active form of EGFR TKD, namely 9.34 kcal/mol.

Figure 3.11 Comparison of erlotinib conformations in active and inactive EGFR TKD.

3.4 Discussion
71

Mutations in the EGFR TKD, including the point mutation L834R, have been identified
in approximately 10% of human non-small cell lung cancer cases which confer the
patient response to be very sensitive to treatment with erlotinib. Several factors contribute
to the effects of mutations on the kinase inhibitor efficacy, at the core of which is changes
in the inhibitor binding. To address this question, the Ki values of erlotinib binding to
wildtype and mutant EGFR TKD have been reported by several groups. Some groups
have reported similar Ki values for erlotinib (or Gefitinib, an inhibitor with very similar
clinical and biochemical properties to erlotinib) forin both wildtype and mutant systems
[83, 101]. However, others have reported higher binding affinities for the L834R EGFR
TKD relative to Wildtype [284], even though the crystal structures of gefinitib with both
wildtype and L834R mutation EGFR TKD show no conformational differences in
inhibitor binding.
The structure of the wild-type EGFR TKD has been determined in both active and
inactive conformations. The crystal structure in complex with erlotinib [248] reveals an
active conformation of the kinase, while the structure of wild-type EGFR kinase in
complex with lapatinib [276] shows the kinase adopting an inactive conformation. Hence,
it is widely believed that erlotinib is more effective at inhibiting the activated EGFR
kinase and that lapatinib is more effect at inhibiting the inactive EGFR TKD.
Considering the different conformational preferences of the kinase inhibitors, the
dynamic equilibrium between the active and inactive conformations of the ErbB kinase
domains may have an important role in determining their sensitivity to these inhibitors. It
has been proposed that Leu834 plays an important role in stabilizing the inactive
72

conformation of the EGFR kinase domain and mutation L834R likely destabilizes the
inactive conformation and shifts the equilibrium toward the active conformation, hence
leading to possible kinase activation as well as higher sensitivity to erlotinib [284].
Therefore, one possible explanation is that this increase in affinity for gefitinib results
from the stabilization of the active-like conformation of the EGFR TKD due to mutation.
Hence, a detailed mechanistic picture of how erlotinib binds to different EGFR kinase
conformations and how the mutation will affect the binding in each conformation is
necessary.
Most of the experimental data have also dealt with the total population of EGFR kinase
and not the relative fractions of active and inactive states. Computational analysis and
simulations are therefore a vital complement to experiments in defining the equilibrium
between the conformational states. Our results confirmed that the L834R mutation does
not significantly change the inhibitor binding free energy to EGFR TKD in the active
form. Moreover, we have shown that it is very likely that erlotinib binds to the inactive
EGFR TKD with similar affinity as that to the active EGFR TKD. This finding highlights
the importance for future investigations to address the effects of different kinase
conformations on the inhibitor binding as well as inhibitor sensitivity.
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Chapter 4 A Multiscale Computational Approach to
Dissect Early Events in EGFR Mediated Differential
Signaling

and

its

Relevance

to

Oncogenic

Transformations
4.1 Introduction
It is well established that alteration or over expression of EGFR is correlated with a
variety of clinical cancers [173, 233]. Hence, small molecule receptor tyrosine kinase
inhibitors for EGFR TKD are also of significant interest as cancer therapeutic drugs.
Small molecule tyrosine kinase inhibitors (e.g., anilinoquinazoline compounds such as
gefitinib and erlotinib), which are ATP analogues [9, 10, 134, 179, 210], have been
shown to exhibit growth inhibitory effects against a wide variety of human tumors [57,
58, 60, 59, 61]. The RTK inhibition approach has shown promise in some clinical trials,
but results have been quite mixed [66]. In particular, despite the promise in a small
(demographic) sub-population with significantly advanced disease, clinical responses to
gefitinib and erlotinib varied among population samples. Recently, somatic mutations
L834R, L837Q, G685S, del L723-P729 ins S (there is an alternate clinical numbering
scheme used in the literature with an offset of 24 residues according to which these
mutations are denoted by L858R, L861Q, G719S, del L747-P753 ins S) in the EGFR
TKD domain were reported to correlate with the clinical response of gefitinib and
erlotinib [48, 49, 165, 186]. In vitro, these EGFR mutants demonstrated enhanced
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tyrosine kinase activity in comparison to wildtype EGFR and increased sensitivity to
inhibition [10, 55, 69, 70, 165, 186, 187, 247].
Although, the underlying biochemical basis involving the drug sensitivity to the
mutations is still not clear, the remarkable sensitivity of cell lines carrying gefitinib
sensitizing mutants appears not to be centered around inhibitor or ATP binding affinities,
but rather on other biochemical mechanisms regulating the EGFR TKD activity and
EGF-mediated signaling [107]. In a recent review, the ERbB signaling network is likened
to a bow-tie-configured, evolvable network, displaying modularity, redundancy, and
control circuitry [63]. Under this framework, identifying the role and significance of drug
sensitizing mutations of ErbB receptors would require a systems level understanding of
the signaling network [131-133]. This would prove to be of enormous value in effectively
designing kinase inhibitors in development for cancer therapy to target many points along
the signaling pathway simultaneously [83, 135]. Evidence emerging from biochemical
studies points to differential phosphorylation rates associated with different tyrosine
phosphorylation sites in the receptor [7, 139, 247, 273]. Moreover, recent structural
studies have indicated that the clinically identified mutations are able to alter the
regulatory elements within the receptor such as bypassing the dimer-mediated activation
step leading to constitutive activity. Therefore, implications of the effect of such
mutations on preferential signaling can be crucial in shaping the signaling response in
altered cell lines derived from cancer patients.
In this chapter, we adopt a multiscale modeling approach to study EGFR mediated
differential signaling. Through these modeling approaches, we are able to extend the
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prior modeling of EGF-mediated signal transduction by considering specific EGFR TKD
docking interactions mediated by differential binding and phosphorylation of different Cterminal peptide tyrosines on the RTK tail. By modeling signal flows through branching
pathways of the EGFR TKD resolved on a molecular basis, we are able to transcribe the
effects of molecular alterations in the receptor (e.g., mutant forms of the receptor) to
differing kinetic behavior and downstream signaling response. We then extended this
approach to study the effects of EGFR inhibition through TKIs. By employing molecular
docking in combination with network modeling, we are able to quantify changes in the
EC50 of receptor phosphorylation (i.e. 50% inhibition in the cellular context), and EC50
for the inhibition of downstream markers (ERK and Akt) upon treatment with the TKI
erlotinib, in cell-lines carrying both wildtype (WT) and mutant forms of the receptor.
Based upon our results, we conclude that the remarkable efficacy of the inhibitor erlotinib
in the L834R mutant cell line can be attributed to relative gain in efficiency over the WT
in inhibiting the Akt response.

Figure 4.1 Scheme for hierarchical multiscale simulations.
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4.2 Methods
4.2.1 Overall method description
A hierarchical multiscale computational approach (showed in Figure 4.1) based on
molecular dynamics simulations, free energy based molecular docking simulations, and
deterministic network-based kinetic modeling is utilized to study EGFR mediated
differential signaling network.

4.2.2 Signal transduction

Figure 4.2 Phosphorylation model for EGFR. (v1) EGF binds reversibly to EGFR, which increases the
receptor‟s affinity for other ligand-bound receptors (v2). Basal levels of spontaneous dimerization also
occur (v3, v4; not shown). ATP binds reversibly to the catalytic site of the receptor (v5). The transient
ATP-bound EGFR must then encounter a free unphosphorylated peptide on either cytoplasmic tail in a
diffusion-limited step (v8 – v11). (v12) The receptor catalyzes autophosphorylation at either Y1068 or
Y1173 (for clarity, only the Y1068 site is shown). Reactions with an asterisk denote more than one reaction
involving similar kinetics but differing substrates (see Table 4.1).
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Table 4.1 Reaction mechanisms and parameterization for EGFR phosphorylation reactions

Reaction

Mechanism

Parameter values

References

kf = 3 • 10-7 M-1 kr = 3.8 • 10-3
[143]
s-1
s-1

v1

[EGFR] + [EGF]

v2

[EGFR:EGF] + [EGFR:EGF]
[EGFR2]

kf = 1 • 10-7 M-1
kr = 0.1 s-1
s-1

v3 a

[EGFR] + [EGFR]

kf = 1 • 10-7 M-1 kr = 1 • 10 3 [143]
s-1
s-1
Modeled

v5 b

[EGFR2] + [ATP]

v8 c

[EGFR2:ATP]
[EGFR2:ATP:Y1068]

kf = 6.51 • 105 s-1

[EGFR2:ATP]
[EGFR2:ATP:Y1173]

kf = 1.98 • 105 s-1

v12 e

[EGFR2:ATP:Y1068]
[EGFR2Y1068-P]

kcat = 0.29 s-1

[85]

v14 f

[EGFR2:ATP:Y1173]
[EGFR2Y1173-P]

kcat = 0.25 s-1

[85]

v16 g

[EGFR2Y1068-P]

Vmax = 4.5 • 10-7 Km = 5.0 •
[143]
M s-1
10-8 M

v10 d

[EGFR:EGF]

[EGFR2]

[EGFR2:ATP]

Km = 2.4 • 10-8
M-1

[143]

[34]

kr = 769 s-1

[85],
Modeled

kr = 48.1 s-1

[85],
Modeled

[EGFR2]

a

An identical rate equation was employed for spontaneous dimerization of EGFR and EGFR:EGF (v4)

b

Identical rate equations were employed for ATP binding to EGFR2Y1068 (v6) and EGFR2Y1173 (v7)

c

An identical rate equation was employed for Y1068 binding to EGFR2Y1173-P:ATP (v9)

d

An identical rate equation was employed for Y1173 binding to EGFR2Y1068-P:ATP (v11)

e

An identical rate equation was employed for phosphorylation of EGFR 2Y1173-P:ATP:Y1068 (v13)

f

An identical rate equation was employed for phosphorylation of EGFR2Y1068-P:ATP:Y1173 (v15)

g

Identical rate equations were employed for dephosphorylation of EGFR 2Y1173-P (v17) and EGFR2Y1173-P

(v18)

EGF stimulation in a cell results in the simultaneous activation of multiple pathways that
are functionally interlinked [139, 218, 219]. The major pathways we included in this
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chapter are EGF-ERK route and PI3K-Akt pathway. In the EGF-ERK pathway, the
activation of Ras initiates a multistep phosphorylation cascade that leads to the activation
of MAPKs, ERK1, and ERK2 [234]. ERK1 and ERK2 regulate transcription of
molecules that are linked to cell proliferation, survival, and transformation. The PI3KAkt pathway results in the activation of the downstream protein-serine/threonine kinase
Akt. Prior studies have established that some growth hormone-stimulated membrane
tyrosine kinase receptors interact with Shc adapter protein and phosphatidylinositol3'kinase (PI3K), and consequently PI3K-activated Akt inhibits Raf-1 and the following
ERK activity [39, 47, 111, 211]. Akt transduces signals that trigger a cascade of
responses from cell growth and proliferation to survival and motility [174, 197, 214,
234]. The pathways we do not include in our model are phosphoinositol metabolism and
signaling [20, 21, 114, 262, 272], activation and nuclear translocation of STATs [23, 25,
148, 277], clathrin-mediated endocytosis [75, 265] and molecular cross-talk with other
receptor systems [27, 45, 90, 144, 163, 194, 195].
In the kinetic model employed here, signaling through the EGFR is modeled by
combining three published models and augmented by our own set of reactions and
calculations (see Figure 4.2 and Table 4.1). Phosphorylation and docking reactions are
modeled according to Ref. [143]; the MAP kinase pathway reactions are modeled after
Ref. [223]; Akt and PI3K activation are incorporated into the model as described in Ref.
[39]. The similar parameterization and topology in these models allows us to construct a
consistent, stable, and comprehensive system with results in good agreement with
published experimental data [216]. Altogether, our model comprises of 74 reactions and
67 species. 17 of these reactions are novel and represent enhanced molecular resolution
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and detail in EGFR activation, phosphorylation, and docking reactions (Figure 4.2 and
Table 4.1). We note that we restrict our models to the early signaling phase (before
receptor internalization) and thus our model does not take into consideration receptor
signaling from endosomal compartments [115, 112, 113].
Receptor Dimerization. Ligand-bound receptors associate into dimers in a diffusionlimited step [143] with a second-order forward rate constant of 0.1 M-1 s-1 and a reverse
rate of 0.1 s-1 (v2 in Table 4.1). To account for the observed basal levels of
autophosphorylation in the absence of an agonist [54], we also implemented reactions in
which unactivated EGFR can form homo- or heterodimers with other inactivated or
activated receptors (v3, v4 in Table 4.1). Assuming a dissociation constant of 0.1 mM,
we estimate the reverse rate for these reactions (kr,3,4 = 1000 s-1) to be 10,000-fold greater
than that of two activated receptors.
Receptor Phosphorylation. In our model, the phosphorylation of the receptor occurs in
three steps: (1) ATP binds reversibly to the active site of EGFR (v5-v7 in Table 4.1). The
wildtype Km = 24 nM reported by [34] was used for this reaction. (2) An
unphosphorylated tyrosine peptide on the cytoplasmic tail diffuses and binds transiently
to the active site (v8-v11 in Table 4.1). Peptide dissociation rates were parameterized
according to values reported in the literature [85]. The reverse rate for these reactions was
estimated by setting koff = (kon) • e+G/kT, where ΔG was calculated from the Km for each
peptide. (3) In the third step, a phosphate group from ATP is transferred to either Y1068
or Y1173 (v12-v15). kcat values of 0.29 s-1 and 0.25 s-1 were used for catalysis of Y1068
and Y1173, respectively [85]. By undergoing two rounds of phosphorylation, a single
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receptor may be phosphorylated at both sites. Phosphorylation reactions and parameters
are listed in Table 4.1.
Docking interactions. Differential signaling is modeled by allowing only a subset of
signaling proteins to bind to each form of the phosphorylated receptor (Figure 4.2). Using
the most comprehensive model of network interactions to date [184], we partition
signaling proteins into two groups. Grb2 and PI3K bind only to Y1068; PLCγ and Shc
bind only to Y1173 [139, 247]. Higher order docking reactions are modeled as described
previously [39, 143, 223].
Inhibition reactions. To model competitive inhibition by an ATP analog, we added the
reaction EGFR + inhibitor

EGFR:inhibitor in our model. The inhibition constant (KI)

of erlotinib for WT ( 17.5 nM ) and L834R ( 6.25 nM ) receptors are obtained by
obtained from published experimental data [48].
The complete model is assembled and analyzed using the Systems Biology Toolbox for
MATLAB (http://sbtoolbox.org/). Simulations are carried out using the CVODE solver
from Sundials (http://www.llnl.gov/CASC/sundials) along with a compiled version of the
model.

4.2.3 Molecular dynamics (MD)
An active conformation of the wildtype EGFR TKD domain is modeled using the 1M17
structure [248, 288] by adding hydrogen atoms and missing residues using the
CHARMM [37] biomolecular simulation package. The resulting conformations are first
energy minimized and subsequently equilibrated by performing molecular dynamics. A
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L834R mutant active structure was also generated on the basis of the wildtype structure
(mutation performed using the INSIGHT II package [4]) and subsequently energy
minimized using CHARMM. The proteins are then solvated and neutralized by placing
ions; the solvated models are minimized and equilibrated using the NAMD program [182]
with periodic boundaries enforced and long-range electrostatics taken into consideration.
Each system is subjected to a constant temperature and constant pressure molecular
dynamics runs at 300 K and 1 atm followed by constant temperature equilibrium at 300K
for 10 ns.

4.2.4 Molecular docking
Molecular docking is used to predict ligand binding in the absence of a ligand-bound
crystal structure and functional affinity data. We employ AutoDock, an automated
docking tool designed to predict how small molecules, such as substrates or drug
candidates, bind to a receptor of known 3-dimensional structure [178]. We perform a
global conformational search using a multiple conformation docking strategy, in which
the protein flexibility is taken into account implicitly by using multiple conformations,
i.e., by sampling from several (100) frames of the 10 ns molecular dynamics trajectory.
The lead docked conformations (based on lowest binding free energy) are extracted and
clustered on the basis of their root-mean-squared deviation or RMSD values.
As control simulations, we validated the predicted results of our docking protocol by
applying our method to study ligand binding to enzymes for which a solved crystal
structure of the bound complex was available. In all three cases, namely ATP binding to
cAMP, ATP binding to insulin receptor kinase, and erlotinib binding to EGFR TKD, the
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predictions of the location and conformation of the bound ligand matched the
crystallographic data very closely (data not shown). This multiple conformation docking
protocol is employed in calculating the ATP, inhibitor, and Y1068/Y1173 peptide
substrate binding affinities.

4.3 Results
4.3.1 Substrate binding affinities for EGFR TKD.

MG2+
ATP
Tyrosine in Peptide
D831
A-loop
D813

Catalytic
loop

Figure 4.3 Binding modes for ATP (cyan) and the optimal peptide sequence (yellow) in the EGFR TKD
domain. The geometry of the active site is consistent with that prescribed for an ideal two-metal-ion
catalyzed mechanism and reveals a state that is poised for the phosphoryl transfer reaction. The alignment
of the two divalent Mg2+ ions as well as the catalytic aspartates D813 and D831 are also shown.

In order to explore the C-terminal peptide-substrate-bound pre-catalytic conformation, we
dock EGFR TKD substrate peptides to the catalytic site. First, we focus on an optimal
peptide sequence EEEEYFELV as a control. This optimal sequence is selected for a
maximal value in kcat/KM among EGFR TKD substrate peptides [246]. Based on 50083

1000 different genetic algorithm runs for docking of this peptide to EGFR TKD, we
select the best binding conformation for binding as one that yields the lowest binding free
energy simultaneously with the correct orientation for the tyrosine binding into the active
site. The latter criterion is essential in ensuring that kcat is not significantly compromised
in obtaining a stronger binding. We depict in Figure 4.3, the peptide conformation bound
to the active site, which is seen to be ideally poised for a two-metal-ion catalyzed
phosphoryl transfer from ATP to the bound tyrosine [176, 250]: i.e., the relative positions
of the ATP, Mg2+ ions, and the catalytic aspartates are in good alignment. Encouraged by
this result, we performed peptide docking simulations for two substrate peptides (each
being seven amino acids long) corresponding to the Y1068 (VPEYINQ) and Y1173
(NAEYLRV) sites of the C-terminal tail for both wildtype and L834R mutant structures.
Based on similar criteria of lower binding free energy and optimal catalytic geometry, we
calculated the peptide binding affinity corresponding to sites Y1068 and 1173 for
wildtype and L834R mutant systems. Upon mutation, the calculated KM for the Y1068
peptide decreased 20-fold (calculated G[wildtypeL834R]= -2.2 kcal/mol), while the
calculated

KM

for

the

Y1173

peptide

increased

4-fold

(calculated

G[wildtypeL834R]= +0.9 kcal/mol). Analysis of the binding modes reveals that the
relative alignment of the tyrosine with respect to the catalytic site is ideal (2.2 Å in the
observed distance  between Tyr OH oxygen and Asp 813 O2) for the two peptide
tyrosines binding to wildtype, with the two mutant systems showing a 0-1.5 Å deviation.
The differences can translate into differences in kcat values associated with the tyrosine
phosphorylation. Assuming a harmonic energy profile along the reaction coordinate 
with a force constant K, the work done in reducing this distance is given by 1/2K2. The
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value of K is obtained by recording the fluctuations of  in the MD simulations
(K=kBT/2=0.77 kcal/mol/Å2 for the wildtype and 1.01 kcal/mol/Å2 for L834R), where
 is the standard deviation associated with the fluctuations in  in the trajectories). The
normalized values of kcat/KM can then be compared for the four systems at the same value
of =2.2 Å); the relative increase in kcat/KM: 1068 for the L834R in comparison to the
wildtype is 20-fold (increase by 1-order of magnitude), while the relative decrease for the
1073 is 200-fold (decrease by 2-orders of magnitude). This differential sensitivity
translates into differences in phosphorylation of the associated tyrosine sites, which
ultimately leads to differential signaling and downstream activation in the EGFR
network: the Y1173-phosphorylation is associated Shc mediated ERK activation and
Y1068-phosphorylation is associated with Akt activation [139, 247].

4.3.2 Differential signaling through EGFR TKD
By employing the deterministic model we have calculated transient evolution of the EGFmediated signaling network under a variety of initial conditions and parameter values. In
particular, we have focused on two pools of normal ([EGFR]=100 nM or 33,000
receptors per cell) and over expressed ([EGFR]=2000nM or 660,000 receptors per cell)
EGFR concentrations, each in the absence (serum starved, [EGF]=0 nM) and presence
(serum cultured, [EGF]=8 nM) of the EGF ligand. Since our molecularly resolved model
is currently focused on differential signaling through Y1068 and Y1173 phosphorylation
sites of EGFR TKD, we track the integrated response of ERK and Akt phosphorylation
levels in our simulations. Each output state was quantified according to the peak level of
phosphorylation over the simulated time of 1000 s. Specifically, we perform a two85

dimensional scan over kcat/KM values associated with Y1068 and Y1173 phosphorylation
in which the respective kcat/KM values are allowed to deviate from their default (wildtype)
value over a logarithmic range of five log units. The result is a two-dimensional matrix in
which each element represents output from a single simulation involving a unique pair of
parameters (see Figure 4.4).
EGFR Normal Expression

EGFR Over Expression

[EGFR] = 100 nM

[EGFR] = 100 nM

[EGFR] = 2000 nM

[EGFR] = 2000 nM

[EGF] = 0 nM

[EGF] = 8 nM (+)

[EGF] = 0 nM

[EGF] = 8 nM (+)

Activation

ERK

AKT

Figure 4.4 Calculated ERK and Akt phosphorylation levels in units of nM (peak-levels over the time course
of 1000 s) under serum starved (EGF-) and serum cultured (EGF+) conditions for cell types with normal
EGFR expression and EGFR over expression. In each panel, the blue circle denotes the wildtype levels and
the green square denotes those relevant to the L834R mutant cell lines.

4.3.3 Inhibition of EGFR phosphorylation
Next, we examined the sensitivity of WT and mutant systems to inhibition in the cellular
context by calculating receptor phosphorylation over a range of erlotinib concentrations.
Simulations were performed for both „normal‟ ([EGFR] = 100 nM) and „over-expressed‟
([EGFR] = 1000 nM) systems. All simulations were performed with (50 ng/ml or 8 nM)
or without ligand (EGF) stimulation.
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Figure 4.5 Relative inhibition of receptor phosphorylation. Tyr phosphorylation levels relative to that
without inhibitor are plotted.

The EC50 (inhibitor concentration at which 50% of the activity is suppressed in the
cellular context; this is different from IC50 because the non-linear and temporal effects
due to signal-transduction is accounted for) for L834R was 50-fold lower (see Figure 4.5:
A&B) than that of the WT (100 nM vs. 5000 nM) in the presence as well as absence of
ligand. There were also no prominent differences between the inhibition at 1068 and
1173 sites. In over-expressed systems, there was no significant difference in EC50 among
the four groups (Figure 4.5: C&D). All had an EC50 near 1000 nM.

4.3.4 Inhibition of downstream activation
The sensitivity of downstream signaling molecules ERK and Akt to inhibition for a range
of erlotinib concentrations is shown in Figure 4.6.
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Figure 4.6 Inhibition of ERK and Akt activation in systems with normal receptor expression. Responses
plotted relative to that without inhibition under the same conditions.

In normal expression systems (Figure 4.6 A&B), there was a nearly 7-fold increase in the
efficiency of pERK inhibition for L834R (EC50 = 100 nM) compared to WT (EC50 = 700
nM) with and without ligand present. With respect to Akt activation, there was a 4-fold
decrease in EC50 for L834R compared to WT (300 nM vs. 1200 nM) with and without
ligand present. For the case of over-expressed receptors (Figure 4.6 C&D), inhibition of
pERK is 4-fold more efficient for L834R compared to WT, while pAkt inhibition is
almost 10-fold more efficient for the L834R mutant, although significantly more erlotinib
is required to achieve inhibition (EC50=40 μM). This result is consistent with the
dramatically elevated Akt levels expected in systems that bear both the L834R mutation
and a higher receptor count.

4.4 Discussion and conclusion
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Based on an integration of a large body of knowledge accumulated over the years, the
modular nature of EGFR-mediated signaling has become apparent [63, 131]. Through a
hierarchical multiscale modeling scheme, we have realized a molecular resolution to this
system-level view, which can potentially augment our predictive as well as
comprehensive capabilities and rationalize the changes in early signaling characteristics
of altered and mutant cell lines. Our overall findings are summarized below.
Our results from the free energy docking simulations suggest enhanced binding of the
inhibitor erlotinib to the L834R mutant system in comparison to wildtype binding. Our
results also reveal preferential binding and phosphorylation of certain C-terminal tyrosine
substrates (but not others) to the L834R mutant in comparison to the wildtype: that is, the
calculated change in the turn over rate (kcat/KM) upon the L834R mutation is markedly
different for the Y1173 peptide in comparison to the Y1068 peptide. This results in a
differential sensitivity at the receptor level. Specifically, the estimated increase in kcat/KM
for the Y1068 peptide is 10-fold in comparison to a decrease of 100-fold for the
Y1173 peptide. Thus, we expect to see a net increase in phosphorylation of Y1068 and a
net decrease in phosphorylation of Y1173 for the L834R mutant, in comparison to
wildtype levels. The biochemical results of Sordella et al. [247] and Chen et al. [51]
corroborate this view qualitatively; in these studies, the immunoblots measuring the
degree of phosphorylated receptor at the Y1173 site show a modest decrease for the
L834R mutant in contrast to a strong increase for the Y1068 site, both in comparison to
their respective wildtype measurements.

89

Our systems level simulation illustrates how the altered affinities at the receptor level for
the wildtype and L834R translates into changes in the downstream response. In Figure
4.4, we explored how the variation in Y1173 and Y1068 phosphorylation affects the peak
responses of ERK and Akt for two different EGFR concentrations, each in the absence or
presence of EGF stimulation. The calculated responses for the wildtype values are
highlighted by the blue circles at the origin of each of the panels. The responses for
L834R are identified by the green square centered at a (kcat/KM)/(kcat/KM)wildtype value of
1/100 (-2 in log10 units) for Y1073 and 10 (+1 in log10 units) for Y1068. Owing to the
constitutively active characteristic of the L834R mutant, the signals relevant for the
L834R system (even in the absence of EGF) are analogous to those in the panels with
EGF stimulation. As indicated by the color maps in these two scans, increasing the
degree of phosphorylation of the Y1173 site (positive x-direction) leads to an overall
increase in ERK response. This finding is consistent with our model which is based on
Y1173 being an important docking site for the Shc and Grb-2 adaptors that lead to Ras
activation and subsequent Erk phosphorylation. For normal EGFR expression, the
calculated ERK response in the absence of EGF is low for the L834R mutant (0.01 nM)
but negligible (zero) for the wildtype. In the presence of EGF the ERK response for
L834R is 7-fold lower than that for the wildtype. For over expressed EGFR, the ERK
activation is 7-fold higher in L834R compared to wildtype both in the presence as well as
in the absence of EGF stimulation. Thus, Erk stimulation is higher in EGFR overexpressed cells. The Akt response relative to the wildtype is 2-fold higher for the mutant
cells under no EGF stimulation and about the same under EGF stimulation for normal
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EGFR expression. The Akt response does not seem to be affected by mutation for high
EGFR expression either in the presence or absence of EGF.
Our calculated responses for ERK and Akt signaling for normal EGFR expression agree
with the qualitative experimental observations of Sordella et al. [247] and Tracy et al.
[259]: namely, that the Erk stimulation levels decrease and the Akt levels are maintained
for the mutant cells with normal EGFR expression levels. This preferential activation of
Akt in L834R mutant cell lines observed in these experiments is consistent with the
systems level predictions from our simulations. Moreover, our calculations predict that
the preferential Akt activation is not featured in EGFR over-expressed cells. Through
multiscale modeling, we have also shown how this framework can be utilized to predict
the efficacy of the inhibition in cell-lines, especially those harboring mutations in the
receptor. We find that the mutant cell line is more susceptible to inhibition by TKIs both
at the level of curbing the receptor phosphorylation as well as that of downstream (ERK
and Akt) activation. Considering that the absolute pAkt levels are 5-fold higher than
those for pERK in the WT and 100-fold higher in the mutant, the remarkable effect of the
drug in non-small-cell lung cancer cell lines carrying the mutation can be attributed to the
gain in efficacy with respect to Akt inhibition.
In light of the overall agreement between simulations and experiment, we can begin to
explore the origins of inhibitor sensitivity in L834R mutant cell lines. The enhanced
sensitivity of erlotinib to L834R mutant arises from a combination of several effects: (1)
the mutant system has a higher binding affinity to the inhibitor; (2) the constitutive
activity of L834R deems the mutant to be a more potent target for therapeutic inhibition;
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(3) The differences in the predicted downstream response (between the wildtype and the
mutant) accounted for by early signaling events can potentially lead to a divergent longterm behavior in the two systems causing a differential sensitivity to inhibition.
In conclusion, we have described the role of a hierarchical multiscale computational
approach in resolving at a molecular level the systems-level model of EGFR-mediated
signal transduction, to help rationalize the collective information emerging from
biochemical, cell biology, and clinical studies. Our approach enables us to transcribe
differences in molecular mechanisms as well as functional activity originating at the
single molecule level into tangible differences in early signaling events. Therefore,
subject to the well appreciated modeling limitations, this predictive capability is useful in
differentiating signaling characteristics of mutant cell lines from the native wildtype case.
This molecular-based refinement of the overall EGFR signal transduction model is a first
attempt at untangling the differential nature of early signaling events triggered by
receptor activation and their consequences in shaping the signal transduction in altered
cell lines derived from different pathologies. A complete model, which is currently being
pursued, will not only require resolving the differential characteristics of all of the
tyrosine phosphorylation sites in EGFR TKD and their associated substrate recognition
properties in EGFR, but also the extension to other Erb family members in the context of
homo- and hetero-dimers. Transactivation of EGFR occurring through ligand-induced
receptor heterodimerization [270] combined with a potential for differential signaling
adds a palette of finer control elements in the ErbB-family signaling network. Indeed,
recent studies have identified possible mutations in ErbB2 that may correlate with drug
sensitivity in different cancers [155, 156]. The computational tools described here are
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ideal for assessing the likely effect of novel EGFR and ErbB2 mutations and determining
whether the drug-sensitizing mutations implicated in non-small-cell lung cancer also
occur in other cancers. We believe that our model driven approach will in the long-term
significantly impact the optimization of future small molecule therapeutic inhibition
strategies.
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Chapter 5 A Flexible-protein Molecular Docking Study
of the Binding of Ruthenium Complex Compounds to
PIM1, GSK-3β, and CDK2/Cyclin A Protein Kinases
5.1 Introduction
As the overall protein fold is conserved in the kinase family, one of the major challenges
is to understand the molecular basis for inhibitor sensitivity and to design small-molecule
compounds which are highly selective (specific) to the targeted protein kinase. Progress
towards the design of selective small-molecule kinase inhibitors based on the exploitation
of distinct features presented by ATP-binding site has recently been reviewed [258], [183].
Vast majority of specific enzyme inhibitors are small organic molecules that gain their
specificity by a combination of weak interactions, including hydrogen bonding,
electrostatic contacts, and hydrophobic interactions. Recently, a novel strategy has been
introduced for the design of small-molecule enzyme inhibitors by using substitutionally
inert organometallic scaffolds [31, 172], based on the hypothesis that complementing
organic elements with a metal center may provide new opportunities for building threedimensional structures with unique and defined shapes. In particular, a class of halfsandwich ruthenium complex compounds based on the scaffold shown in Figure 5.1have
been reported to show high affinities and promising selectivity profiles for protein
kinases and lipid kinases [11, 32, 278].
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Figure 5.1 Chemical structure of ruthenium complex compound (named compound 1 in this chapter)
analyzed in this chapter. The R- enantiomer is depicted on the left and the S-enantiomer on the right.

The new ruthenium complex compounds are designed to mimic the shape of
staurosporine, a well-known protein kinase inhibitor, by replacing the indolocarbazole
alkaloid scaffold with metal complexes in which the structural features of the
indolocarbazole heterocycle is retained. The ruthenium metal center plays a structural
role by organizing the organic ligands in the three-dimensional space. As shown in Figure
5.1, the coordination geometry around the ruthenium is pseudo-octahedral, formed by the
pyridocarbazole ligand, the CO group oriented perpendicular to the pyridocarbazole
plane, and the cyclopentadiene (Cp) moiety. The compound was designed to bind with
the kinase by forming hydrogen bonds to the backbone residues at the hinge region of the
kinases. However, unlike staurosporine, which is a nonspecific nanomolar inhibitor for
most protein kinases, these ruthenium half-sandwich compounds show remarkable
selectivity profiles. In particular, profiling the racemic mixture of (R/S)-1 against more
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than 50 protein kinases in vitro shows high selectivity of this class of compounds for
PIM1 (IC50= 3nM, 100µm ATP) and GSK-3β (IC50= 50nM, 100µm ATP)[11].
Interestingly, the phylogenetically and structurally closely related cyclin-dependent
kinases (CDKs) are not significantly inhibited, with IC50= 3M (100µm ATP) for the
CDK2/cyclin A complex [11].
Table 5.1 Sequence alignment of residues around active site of the three protein kinases, PIM1, GSK3, and
CDK2. Residues which are significantly different are colored.

Kinases
PIM-1

N-terminal lobe

Linker region

L44 G45 S46 F49 V52 A65 I104 L120 E121 R122 -

C-terminal lobe
P123 E171 L174 I185 D186

GSK-3β I62 G63 N64 F67 V70 A83 V110 L132 D133 Y134 V135 P136 Q185 L188 C199 D200
I10 G11 E12 Y15 V18 A31 V64 F80 E81 F82 L83 H84 Q131 L134 A144 D145
CDK2

Sequence alignment analysis (Table 5.1) shows a high degree of conservation among the
ATP binding pocket residues of the three kinases. Superposition of the kinase active sites
using the α-carbon atoms of the residues around the ATP pocket also shows that the
structure of the binding site is highly similar among the three kinases (Figure 5.2).
Despite these similarities, differences in specific amino acid positions are noted (colored
in Table 5.1 and labeled in Figure 5.2) , which possibly have a bearing on the differences
in the binding interactions, and hence the inhibitor selectivity.
Although it is of great interest to understand the interaction of ruthenium compounds
with the three protein kinases in atomic details, [217, 267] only one crystal structure, i.e.,
PIM1 bound with (R)-1, is currently available. It is not clear how the other enantiomer,
(S)-1 is bound to PIM1. The bound conformations of both (R)-1 and (S)-1 are not known
from experiments either. In this chapter, we modeled the interactions between the
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ruthenium scaffold and three protein kinases, PIM1, GSK-3β and CDK2/cyclin A,
targeting the selectivity profile of the compound.

Figure 5.2 Structural alignment of the ATP binding pockets of three protein kinases, PIM1, GSK3, and
CDK2/CYCLIN A.

Molecular docking is frequently used to predict ligand binding in the absence of ligandbound crystal structures and functional affinity data [36, 109]. While ligand flexibility is
accounted for in most docking programs, many treat the protein as a rigid body. However,
in practical scenarios in which the receptor structure is derived either from an
experimentally determined structure of the apo- kinase or from a structure where the
kinase is complexed with a different ligand, the rigid-receptor docking often fails to
predict proper bound conformation. Hence, efforts have been made to account for the
protein flexibility [50, 275]. In this chapter, we applied the ensemble docking procedure
to predict bound conformations of ruthenium compounds (R/S)-1 against the three protein
kinases PIM1, GSK-3β and CDK2/cyclin A. Our docking results reveal the proteinligand interaction and suggest possible structural factors that may give rise to different
binding affinities of the proteins.
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5.2 Methods
The flow chart in Figure 5.3 depicts the ensemble docking protocol we have followed. To
summarize, protein conformations are sampled with all-atom molecular dynamics (MD)
simulations with explicit solvent. Charges and geometry of the ligands are calculated
using electronic structure (ab-initio) methods. The ligands were then docked into each of
the protein conformations using the docking program AutoDock3.0. The predicted bound
conformations of ligand are subsequently clustered.

Figure 5.3 Flow chart of ensemble docking method

5.2.1 Ab-Initio

electronic-structure

compounds

98

calculations

of

Ru-complex

The geometries of both enantiomers of compound 1 are optimized using the Gaussian 98
[254] program at the Hartree-Fock (HF) [254] level. For the hydrogen, carbon, oxygen
and nitrogen, 6-31G* basis set is used while for the Ru atom, the Los Alamos ECP
(effective core potential) plus DZ (double zeta) basis set (LanL2DZ [136]) is used. The
geometry optimization of the molecule returns the minimum-energy geometry of the
molecule and the spatial electron-density map at 0 K. Following the procedure of Aiken
et.al.[6], the partial (Mulliken) charges on each atom are inferred from the ab-initio
calculations which are used in determining the molecular descriptors of the inhibitor
compound and are used further in the docking calculations.

5.2.2 Protein conformation preparation
The native and non-native protein conformations of PIM1 kinase are constructed based
on two different crystallographic structures from the protein data bank: (1) the structure
of the PIM1/(R)-1 bound complex (PDB ID: 2BZH), and (2) the structure of PIM1 bound
to an ATP analog (PDB ID: 1YXT). For the GSK-3β and CDK2/cyclin A systems,
conformations derived from crystal complex structures with the ATP analog (1I09 for
GSK-3β and 1QMZ for CDK2/cyclin A ) are employed in the docking simulations. Four
apo-kinase conformations are generated based on these crystal structures, by removing
ligands and adding hydrogen atoms and other missing residues using CHARMM [37]
biomolecular simulation package.
To generate an ensemble of conformations for each kinase, molecular dynamics (MD)
simulations for each protein kinase are performed with the respective crystal structures
serving as the starting conformation. The proteins are explicitly solvated using the TIP3P
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model for water and neutralized by placing ions (sodium and chloride) at an ionic
strength of 150 mM. The ions are placed at positions of electrostatic extrema predicted by
the mean-field Debye-Huckel calculations. The solvated models are energy minimized,
heated to 300 K, and equilibrated at constant temperature and constant pressure (300 K
and 1 atm) using the NAMD simulation package [141] in conjunction with the
CHARMM27 force-field [166]. All our simulations are performed on a fully periodic
system and include long-range electrostatics using the Particle Mesh Ewald algorithm
[14]. The extent of the equilibration phase is determined by tracking the plateau behavior
of the RMSD (root mean square deviation) of the protein calculated with respect to its
starting conformation. For each protein kinase system, 10 ns of dynamics runs are
generatedFor each system, we extract 100 protein conformations at uniform intervals
from the last 8 ns of the respective trajectories for use in our ensemble docking protocol.
In order to make the comparison of different systems easier, all the protein conformations
are aligned with respect to the PIM1 coordinates in 2BZH structure based on residues
within 15 Å of the ATP binding site.

5.2.3 Docking protocol
AutoDock3.0.5 program [178] is used for docking simulation. For each protein structure,
the non-polar hydrogen atoms are merged to heavy atoms and Kollman charges and
solvation parameters are then assigned to the protein atoms using AutoDockTool (ADT)
[1]. Grid maps for each protein conformation of dimension 126126126 points with a
grid spacing of 0.184 Å are constructed, encompassing the entire ATP binding site. The
Lamarckian Genetic Algorithm (LGA)[178] is applied to explore the conformational
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space of the ligand using the scoring function. In each docking run, the initial population
is set to 50 individuals, the maximum number of energy evaluations is set to 108, and the
generation of GA run is set to 10,000. 30 GA runs are performed for each protein
conformation. This choice for the set of run-parameters is adequate to achieve
convergence of the docking results.

5.2.4 Ligand conformation clustering
Ligand conformations are clustered using the hierarchical clustering algorithm in Matlab
[2]. For each docking run, the root mean squared deviation (RMSD) value between each
pair of all docking-generated ligand conformations (30 for single conformation docking
with the crystal structure and 3000 for ensemble docking) are calculated and used as the
distance matrix to build a hierarchical tree by progressively merging clusters using
unweighted average distance of each cluster. Then a cut-off RMSD value is used to
cluster ligand conformations based on the hierarchical tree. We used the pairwise RMSD
distribution of docked conformation to determine the optimal radius [152]. The
distribution of pairwise RMSD of all the docked conformations are depicted in Figure
5.4. The minimum RMSD values after the first peak are chosen as the optimal clustering
radius, namely, 2.0 Å for single conformation docking and 2.5 Å for ensemble docking.
The conformations with the lowest docked energy in each cluster are reported as the
predicted bound conformations for each system.
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Figure 5.4 Pairwise RMSD distribution histogram of docked conformations for PIM1/(R)-1 system. A:
single conformation docking, B: Ensemble docking

5.3 Results
5.3.1 Ensemble docking protocol counts the protein flexibility and
improves the prediction of bound complex structure
In this chapter, we are interested in predicting and comparing the interaction between Rucomplex compound and three protein kinases, PIM1, GSK-3β and CDK2/cyclin A to
provide insight on structural basis of the selectivity profile of the compound. Docking
ligand to non-native protein conformation (apo- protein or protein complexed with other
ligands) is still a challenging task. To account for the protein flexibility, we used the
ensemble docking protocol, i.e., docking the Ru-complex compound into an ensemble of
protein snapshots generated by MD simulations.
The protocol was first tested using PIM1/(R)-1 system, where a crystal structure of the
exact complex has been solved. To examine the reliability of different docking protocols,
we performed two test cases to dock the (R)-1 compound to the PIM1 protein kinase. The
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first test was the docking to the PIM1 structure (PDB ID: 2BZH) in which (R)-1 was cocrystallized. In the second test, the crystal structure of PIM1 (PDB ID: 1YXT) bound
with an ATP analog was used instead. In each test, both the traditional docking protocol
based on single protein structure and the ensemble-docking (using 100 conformations)
protocol were applied to generate complex structures. The actual complex structure
(2BZH) determined from crystallography serves as the “native” pose, or a reference to
evaluate the docking results.

Figure 5.5 RMSD relative to the reference structure versus the docked energy score for each predicted
conformation of compounds (R/S)-1 to two PIM1 structures, i.e. the native structure of PIM1 bound to
compound (R)-1 (PDBID: 2BZH) and the non-native structure of PIM1 bound to an ATP analog
(PDBID:1YXT). The symbols ■ corresponds to single conformation docking results and the symbols ○
correspond to ensemble docking results.

Our results in Figure 5.5 show that the predicted ligand-bound structures from singleconformation docking can be classified into several clusters with similar dock energies.
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When ensemble docking was used and the flexibility of the protein was thus accounted,
more complex conformations were generated and a better discrimination between the
lowest (dock) energy conformations of different clusters was observed. Furthermore,
conformations similar to the native pose emerge among the top clusters when ranked by
dock energy.

Figure 5.6 Predicted bound conformations of the inhibitor with the lowest RMSD to the reference structure
from single conformation and ensemble conformation docking are aligned together with crystal structure.
Blue: the single conformation docking of compound (R)-1 to the native PIM1 structure (PDBID: 2BZH).
Orange: Ensemble conformation docking of compound (R)-1 to the PIM1 ensemble of structures based on
native PIM1 structure. Tan: Single conformation docking of compound (R)-1 to the non-native PIM1
structure (PDBID: 1YXT). Pink: Ensemble conformation docking of compound (R)-1 to the ensemble of
PIM1 structures based on non-native PIM1 structure. Red: Crystal structures (PDB ID: 2BZH).

All predicted complex structures were superimposed against the native pose (2BZH),
with the closest one from each docking task shown in Figure 5.6. We also listed the
parameters of the critical hydrogen bond between the NH group of the inhibitor and
GLU121 of the protein in Table 5.2. When single-conformation docking was used in
combination with the exact protein structure (2BZH), not surprisingly, the results (blue
structure) closely resemble the native pose present in the same crystal structure. However,
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when the approximate protein structure (1YXT) was used, the single-conformation
docking failed to correctly present the critical hydrogen bond in the native pose. In
contrast, when ensemble docking was applied on either the exact or the approximate
protein structure, reasonable bound conformations (orange and pink structures) with the
proper hydrogen bond and consistent with the native pose were among the sampled poses.
Table 5.2 Parameters of the hydrogen bond between the NH group of compound 1-R and the residue
GLU121 in PIM1 for complex conformations in Figure 5.6.

Structures

Distance (Å)

Angle ( Degrees)

Red (Crystal Structure)

2.0

151.02

Blue (native/single docking)

1.72

140.16

Orange (native/ensemble docking)

1.76

137.39

Tan (nonnative/single docking)

3.55

114.33

Pink (nonnative/ensemble docking)

1.65

135.03

To show how the ensemble of conformations provides a more suitable ligand docking
environment, the 100 conformations of the PIM1 ensemble corresponding to non-native
structure (PDBID: 1YXT) are aligned together and depicted in Figure 5.7 (A). It is
evident that the snapshots in our ensemble simulations sample the kinase flexibility by
exploring both backbone and side chain fluctuations around the crystallographic
conformation used as the starting point for the MD simulations. In Figure 5.7 (B), the
initial non-native PIM1 conformation (PDBID: 1YXT) and the conformation which binds
the inhibitor with the lowest dock energy are aligned together and the key residues
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around the binding pocket are depicted. The comparison reveals the shifting of key
residues, in particular, GLU171, ASP128 and ASP186, from the initial non-native
structure, and the rearrangement of the flexible Gly-rich loop (Gly45) to better position
the CO group and the Cp ring.

Figure 5.7 (A) Snapshots of PIM1 conformations generated from MD simulations based on the non-native
PIM1 structure (PDBID: 1YXT). Snapshots are aligned by overall RMSD, and colored by atom types. The
black conformation is the crystallized non-native PIM1 conformation. (B) Protein conformation
comparison between the non-native crystallized structure of PIM1 (PDBID: 1YXT, gray) and the predicted
protein bound conformation with the lowest RMSD to the reference structure using the ensemble
conformation docking corresponding to this non-native PIM1 system (orange).
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Figure 5.8 Top two ranks of conformations of compound (R/S)-1 bound to PIM1 predicted by ensemble
docking. (A), (B): compound (R)-1. (C), (D): compound (S)-1. We denote the similar conformations in (A),
(C) as conformation I and those in (B), (D) as conformation II.

As we noted in Figure 5.6, the non-native PIM1 structure fails to account for the
conserved hydrogen bond between GLU121:O – (R)-1:H1, which is captured after the
slight rearrangement of active-site residues using the ensemble docking protocol. Thus,
the implicit protein flexibility in our protocol yields a better docked score for this
conformation. Even though protein kinases are known to assume multiple conformational
states in a rugged energy landscape [94] which are not exhaustively sampled in short
MD simulations, we find that by sampling the fluctuations of protein conformation
around a given initial state of our control system, our ensemble protocol demonstrates
clear improvement in the prediction of the ligand-bound structure of the complex.
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5.3.2 Two dominated conformations are predicted for (R/S)-1 to bind
with GSK-3 and PIM-1

Figure 5.9 Top two ranks of conformations of compound (R/S)-1 bound to GSK3-β predicted by ensemble
docking. (A), (B): compound (R)-1. (C), (D): compound (S)-1. We denote the similar conformations in (A),
(C) as conformation I and those in (B), (D) as conformation II.

In Figure 5.5, we can see that for both the enantiomers, two conformations are predicted
with relatively lower docking energies compared to other conformation, with RMSDs of
2 Å and 5 Å from the crystallized conformation, respectively.

The two predicted

structures for both enantiomers are depicted in Figure 5.8. In all of the conformations, the
pyridocarbazole moiety forms a hydrogen bond between the maleimide NH group and the
backbone carbonyl oxygen atom of residue within the hinge region (GLU 121) of the
kinase, which mimics the hydrogen-bonding pattern of the ATP as well as staurosporine
with the kinase, and is present in the PIM1/(R)-1 crystal structure. One of the two
conformations, which we denote as conformation I (Figure 5.8 A and C), is very similar
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to the reference structure constructed from crystallography. In the second conformation,
which we denote as conformation II, the CO and Cp groups occupy opposite (swapped)
positions relative to conformation I. Thus the two conformations I and II are related by a
180 flip around an axis through the NH group of the pyridocarbazole moiety. The
existence of conformation II as a stable structure has not been confirmed through
crystallographic studies of the PIM1 kinase. However, this conformation is very close to
a recent structure of compound (S)-2 bound to a lipid kinase (PI3K) [278]. Hence, we
propose conformation II as a competing alternative bound conformation for the inhibitor
bound to the protein kinase.
The same two conformations of compound (R/S)-1 also turn out to be the most dominant
bound conformation with GSK-3β through ensemble docking as depicted in Figure 5.8,
making the binding characteristics of the (R/S)-1 Ru-compound with GSK-3β similar to
those with PIM1.

5.3.3 A unique bound conformation of the ruthenium compound
dominates its binding to CDK2
Our results for the bound conformations (R/S)-1 to CDK2/cyclin A are in stark contrast to
those for PIM1 and GSK-3β. The conformation close to the two conformation for PIM1
and GSK-3β are ranked lower (4th for (R)-1) or not present in our prediction ((S)-1). The
disfavor of these two conformations is an evidence for unfavorable binding of this
compound to CDK2/cyclin A in the native conformation observed in PIM1 and GSK-3β.
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Figure 5.10 The top conformation predicted for both enantiomers bound to CDK2.

While the conformations I and II are not favorable for CDK2, we found the top-ranked
conformation for both enantiomers are very similar and this conformation is unique to
CDK2, not PIM1 and GSK-3β.

In Figure 5.10, we depict the lowest-energy

conformations predicted for CDK2/cyclin A. The lowest-rank conformations for both
enantiomers are found to be quite similar, which strikingly, instead of forming a
hydrogen bond with the hinge region residue, show that the NH group of the
pyridocarbazole moiety points outside the binding pocket. Moreover, the plane of the Cp
ring stacks with the plane of the aromatic PHE80, the gate-keeper residue. The CO group
orients into the small binding pocket formed by ALA144, ASP145, ASN132 and
GLN131. In this conformation, even though the compounds appear to fit nicely within
the CDK2 binding site, there is the distinct lack of the conserved hydrogen bond, which
warrants further investigation and experimental validation of the structure of the inhibitor
complexed to CDK2.

5.4 Discussion
Based on in vitro protein kinases profiling results, it has been determined that the racemic
mixture of ruthenium-based organometalic protein kinase inhibitor scaffold (compound
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(R/S)-1) prefers to inhibit PIM1, GSK-3β over CDK2/cyclin A, even though the active
sites of the three kinases show high degree of sequence and structure similarity. Here, we
find that the ruthenium-based compounds bind in a similar fashion to PIM1 and GSK-3β
but show a novel conformation with marked differences in binding to CDK2/cyclin A.
Based on our structural analysis, we suggest the following reasons to explain this
selectivity: (1) despite the extensive structure and sequence homology, CDK2 differs in
the active site at the location of PHE80, which possibly stabilizes a novel bound
confromation due to a stacking interaction with the Cp ring. This conformaiton also lacks
the characteristic hydrogen bond between the inhibitor and linker region residue of the
kinase and may cause a non-preference to the bound conformation. (2) Compared to
PIM1 and GSK-3β, it is less preferrable for CDK2/cyclin A to bind the inhibitor
(especially the S-isomer) in a conformation which preserves the conserved hydrogen
bond. By aligning the CDK2 structure to PIM1 and GSK-3β, we suggest that residue
PHE80 may play a negative role in positioning the carboxyl group in the pyridocarbazole
plane (Figure 5.2). We therefore suggest to examine the selectivity profile of compound 2
shown in Figure 5.11 (C), which may help to further clarify the possible reason for the
different binding of compound 1 with GSK-3β and CDK2.
Using the existing crystal structure of PIM1/(R)-1 as a control test, we also have shown
that by implicitly accounting for the protein flexibility, the ensemble docking protocol is
able to help refine the structural features as well as discriminate the docked energies
associated with bound conformations of two enantiomeric forms of the inhibitor to the
three kinases. The comparison of results from single point docking and ensemble docking
demonstrate that the traditional docking method based on a single protein conformation is
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sensitive to the protein structure used. Although it generates good docking poses on the
exact protein structure, the results become considerably worse on even a slightly different
protein structure. The ensemble docking represents a significant improvement in this
aspect, yielding consistent results regardless of the initial protein structure used. For the
cases presented above, in which the native pose is unknown, the ensemble docking
protocol is more robust and reliable in sampling the true complex structure.

Figure 5.11 Structure of compound 1 (A), staurosporine (B) and the new compound 2 we proposed for
further testing (C).

In our ensemble docking analysis, we employ the lowest dock energy conformation to
characterize the clusters and show that for PIM1 and GSK-3β, the ensemble docking
protocol ranks the native-like conformations as one of the top clusters. Another popular
choice for scoring the conformations is based on the frequency of an observed cluster
[274]. In our case, we find that many of the top-ranked clusters based on the dock energy
would also be identified by the high-frequency criterion. Hence the two criteria tend to
yield similar predictions for the top-ranked conformations.
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In the ensemble docking protocol we have employed, we do not consider the induced
effect of the inhibitor to the protein conformation, i.e., our docking protocol only
accounts for protein flexibility implicitly. Our assumption is that by sampling the protein
kinase in and around its unbound (apo) state, the dynamics of the protein will account for
the small induced effect and the bound conformations will select for those protein
conformations resulting in lower dock scores. Thus for a good scoring function (with
large correlation between experimental binding affinity and the computed docking score
on an extensive test set of compounds), the ensemble docking is expected to yield
conformations with the lowest binding affinities. We advocate that our ensemble docking
approach is a good first step in cases where we have some knowledge of the protein
structure (through experimental or modeling schemes), such as the prediction of the
bound complex with a new inhibitor scaffold.
We also note the organometalic inhibitor compounds we have studied are very new and
fully flexible force-fields for these inhibitors are not yet available. Therefore, our focus in
this chapter is on the structure prediction of the bound complex as opposed to the free
energy of binding. Once the structural aspects are validated, our predictions are then
logical candidates for a more rigorous evaluation using computationally intensive free
energy protocols in fully atomistic systems [102, 150, 153, 204, 239].

Chapter 6 Perspectives and Future Directions
In this thesis, we developed and applied several computational tools at multiple length
and time scales to model the interaction inhibitors with protein kinases and the catalytic
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reaction mechanism of protein kinases. Our work on EGFR TKD, sheds insight on the
unique properties of this important kinase. Moreover, our understanding of the EGFR
kinase also helps in delineating common mechanisms across the whole protein kinase
family.
In Chapter 2, we predicted how the EGFR TKD recognizes its substrates and performed
the catalytic phosphoryl transfer reaction using a computational protocol combining
molecular dynamics simulations, ensemble molecular docking [161, 274], free energy
calculation[102, 117, 150, 153, 231, 253, 266] and QM/MM. We found that in our
predicted bound conformations the P-1 glutamic acid residue and the hydrophobic amino
acid at the P+1 position interact with a highly conserved motif in the protein kinase
family, namely Val852-Pro853-Ile854-Lys855-Trp856 in EGFR. This motif creates a
binding surface to form hydrophobic contacts as well as hydrogen bonds to residues close
to P-site (P0) tyrosine in the substrate and therefore helps to orient the tyrosine residue
towards the active site. Moreover, our QM/MM simulations show that the EGFR protein
kinase favors the dissociative mechanism, although an alternative channel through the
formation of an associative transition state is also possible. Collectively, our simulations
establish some key molecular rules in operation for the substrate-binding and catalytic
landscapes in the EGFR TKD.
A possible future direction is to extend this work to understanding how mutations affect
substrate binding. The kinase-activating mutation L834R closely locates to the catalytic
site. Based on our simulation results of how EGFR TKD recognize its substrate
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sequences, we are able to further investigate whether mutating the hydrophobic residue
LEU to a positively charged residue ARG will affect the peptide binding affinity.

Figure 6.1 Cumulative free energy (kcal/mol) calculated for bound and unbound systems.

In our preliminary studies, we employ the free energy perturbation (FEP) method to
calculate the binding free energy difference between the wildtype and mutant systems for
peptide Y1068. The FEP results (Figure 6.1 and Table 6.1) showed that L834R mutation
resulted in a binding free energy change (F) of 4.26 ± 4.2 kcal/mol. Our results imply
that the mutation does not increase (but rather decreases) the substrate binding affinity of
the particular peptide. Moreover, by comparing how L834R will alter the binding of
different substrates (Y1068 and Y1173 for example), we can further gain insight on the
effect of this point mutation to differential signaling pathways.
Another promising avenue is to explore the roles of L834R on EGFR kinase catalysis.
Experimental data has shown that the value of the catalytic efficiency (kcat/KM) for the
L834R mutant is ~20-fold higher than that for the wild-type kinase domain [289].
Although the mutated residue in the L834R mutant is not directly involved in the
115

catalytic mechanism, we proposed that the residue is very close to reaction site, three
amino acids displaced from D831, which is critical to catalysis. Moreover, the
phosphoryl transfer reaction is highly sensitive to the electrostatic environment. A
mutation from a neutral residue to a highly positively charged residue close the reaction
area may affect the reaction mechanism, which is a topic of significant interest.
Table 6.1 Cumulative free energy (kcal/mol) calculated for bound and unbound systems. The error bar of
our current calculation is about 4.2kcal/mol

ΔG

ΔΔG

With peptide

No peptide

Forward

47.188

43.247

3.941

Backward

43.3

38.716

4.584

Moreover, the ErbB family of receptors has four members ― the epidermal growth factor
receptor (EGFR or ErbB1 or HER1), ErbB2 (or HER2), ErbB3, and ErbB4. They share
high sequence homology and a common protein structure. Among all the members,
ErbB3/HER3 stands out among the mammalian ErbB receptors since it is generally
considered to be kinase-inactive [62] because a conserved aspartate that is thought to
function as a catalytic base in all protein kinases [167] – deprotonating the substrate
hydroxyl group – is replaced by an asparagine in ErbB3 (N815). HER2, on the other
hand, is thought to be an orphan receptor, with none of the EGF family of ligands able to
activate it. ErbB2 and ErbB3 can only be activated through heterodimerization [18, 62],
and neuregulin-induced ErbB2/ErbB3 heterodimers are considered to be the most potent
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mitogenic signaling complexes in the ErbB receptor network [62, 116]. This presents a
conundrum given current models for ErbB receptor kinase activation, in which one
kinase domain allosterically activates its neighbor and becomes trans-autophosphorylated
as a consequence [140, 287]. In such a mechanism, it is not clear how ErbB2 could be
trans-phosphorylated within an ErbB2/ErbB3 heterodimer unless ErbB3 does have
kinase activity. Our previous work, collaborating with Dr. Mark Lemmon‟s group on
ErbB3 (see Chapter 2), proposed a mechanism for ErbB3 to catalyze the phosphryl
transfer reaction. A further study on the catalysis of ErbB2 and ErbB4 could to gain more
insight on functional and mechanistic inter-relationships among the family members in
controlling substrate activation and signaling.
Finally, our studies on erlotinib (Chapter 3) showed that the L834R does not change the
binding affinity of erlotinib to EGFR TKD in the active state. We further extended our
study to understand how the erlotinib interacts with inactive EGFR TKD. Our simulation
results proposed the possible binding of erlotinib to both active and inactive state of the
kinase. Our collaborator, Dr. Mark Lemmon‟s group, is working on crystallizing the
complex between erlotinib and inactive EGFR TKD. Further investigation of inhibitorbound conformations of the EGFR kinase may illuminate the concept that erlotinib is
effective at inhibiting the ligand-activated EGFR kinase and it may also help to
investigate new compound to inhibit EGFR TKD. This is a promising prospect as it
allows us to target inactive and alternative conformations of kinases for inhibition. Even
though structures of active conformations of several kinases are structurally homologous,
there seems to be a greater variation in the structures of inactive and intermediate forms.
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Thus, the strategy to target conformations different from the active state opens new
possibilities in designing specific kinase inhibitors for cancer therapy.
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